---
title: "Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Product information and disease description"
description: "Formulary evidence on Duravyu (vorolanib intravitreal insert, EYP-1901) in Wet age-related macular degeneration: Product information and disease description. Covers Product description and Place of product in therapy. 276 evidence topics quoted from 92 sources."
canonical: "https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/product-information-and-disease-description"
published: "2026-09-17T18:16:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Summary: development and regulatory status as of November 2026

Vorolanib intravitreal insert (DURAVYU, EYP-1901) is an investigational product and is not approved by the FDA; the FDA has conditionally accepted DURAVYU as its proprietary name. Two identical randomized, double-masked phase 3 non-inferiority trials, designed with feedback from the FDA and the European Medicines Agency, compared vorolanib intravitreal insert 2.7 mg every 6 months with on-label aflibercept 2 mg: LUGANO enrolled 432 participants and LUCIA enrolled 475 participants. On August 17, 2026, EyePoint reported that LUGANO did not meet its primary endpoint (mean change in best-corrected visual acuity, blended weeks 52 and 56) in the full dataset. In an ad hoc analysis that excluded 9 of 211 participants (4%) in the vorolanib insert arm who lost 15 or more letters from causes the sponsor attributed to conditions other than wet AMD, the sponsor reported non-inferiority with a nominal p-value of 0.0096. After LUGANO, the sponsor planned a pre-NDA meeting in the fourth quarter of 2026 and an NDA submission in the first half of 2027, provided that LUCIA results were positive; the NDA was to contain the initial 56-week efficacy and safety data, with year 2 safety data in a supplemental NDA. On October 19, 2026, EyePoint reported that LUCIA also did not meet the primary endpoint (least squares mean BCVA change +2.5 letters with the vorolanib insert and +6.1 letters with aflibercept; difference -3.7 letters), announced that it would conclude both phase 3 wet AMD trials early, without full completion of the second year of each trial, and stated that it would prioritize development in diabetic macular edema. In its third quarter 2026 results of November 12, 2026, EyePoint stated that it will conclude the wet AMD program before completion of the full second year of LUGANO and LUCIA, while allowing additional participants to complete year two to support the safety database for a potential NDA in diabetic macular edema, and that it will complete additional analyses of the LUGANO, LUCIA, and pooled phase 3 datasets to assess next steps in wet AMD. As of November 2026, EyePoint has announced no NDA submission for wet AMD and no launch timing, and no Fast Track, Breakthrough Therapy, or Priority Review designation was identified. Two phase 3 trials in diabetic macular edema (COMO and CAPRI) completed enrollment of more than 480 participants in five months, with topline data expected in the fourth quarter of 2027.

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm); [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm); [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm); [EyePoint LUCIA topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm); [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm); [EyePoint strategic prioritization announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-ex99_1.htm); [EyePoint third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526456889/eypt-ex99_1.htm); [EyePoint second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_1.htm)

<a id="topic-2.1.1-2"></a>

##### Investigational status and conditionally accepted proprietary name

> “has been conditionally accepted by the FDA as the proprietary name for EYP-1901”
> “DURAVYU is an investigational product; it has not been approved by the FDA.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.1.1-3"></a>

##### Phase 3 wet AMD program: design and enrollment

> “Randomized, double-masked, aflibercept controlled, non-inferiority trials assessing the efficacy and safety of DURAVYU 2.7mg in patients with active wet AMD.”
> “The LUGANO trial enrolled 432 patients and the LUCIA trial enrolled 475 patients who were randomly assigned, 1:1, to a DURAVYU 2.7mg arm or an on-label aflibercept control arm.”
> “The Phase 3 program was developed with feedback from both the FDA and European Medicines Agency (EMA).”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.1.1-4"></a>

##### LUGANO topline result: primary endpoint

> “DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD; primary endpoint not achieved in full dataset, confounded by this asymmetric cohort”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

> “DURAVYU did not achieve statistical non-inferiority in full data set”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.1.1-5"></a>

##### LUCIA readout and planned NDA submission

> “The Company remains on track to report topline data from the second wet AMD pivotal Phase 3 LUCIA trial in the fourth quarter of 2026.”
> “The Company anticipates potentially filing an NDA for DURAVYU for the potential treatment of wet AMD in the first half of 2027.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-2.1.1-6"></a>

##### Regulatory strategy after LUGANO and after LUCIA

> “Strategy for NDA Filing in H1 2027, Provided Positive LUCIA Results”
> “Pre-NDA meeting in Q4 2026 based on totality of data”
> “Multiple precedents for NDA approval in ophthalmology following mixed results across two well-controlled Phase 3 trials”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

> “Additional analyses ongoing to assess next steps for DURAVYU as a potential treatment for wet AMD”

Source: [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm)

<a id="topic-2.1.1-7"></a>

##### Planned content of the NDA and supplemental NDA

> “If the wet AMD Phase 3 clinical program is successful, we plan on filing a New Drug Application (NDA) with the U.S Food and Drug Administration (FDA) with the initial 56-week efficacy and safety data. A supplemental NDA (sNDA) is planned for the Year 2 safety data only, once complete.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.1.1-8"></a>

##### Diabetic macular edema phase 3 program

> “Pivotal Phase 3 COMO and CAPRI clinical trials have completed enrollment, together enrolling over 480 patients in five months.”
> “Topline data for both DME trials are anticipated in the fourth quarter of 2027.”

Source: [EyePoint second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_1.htm)

<a id="topic-2.1.1-9"></a>

##### Expedited program designations (Fast Track, Breakthrough Therapy, or Priority Review)

No evidence found.

<a id="topic-2.1.1-10"></a>

##### Regulatory status: No submission planned; Phase 3 trials in wet AMD ending early after LUCIA missed its primary endpoint in October 2026

> “WATERTOWN, Mass., November 12, 2026 (GLOBE NEWSWIRE)”
> “We will conclude the wet AMD program before completion of the full second year of the Phase 3 studies for both LUGANO and LUCIA, while also allowing additional patients to complete year two to support the necessary safety database for a potential new drug application for DME.”
> “We will complete additional analyses of both the LUGANO and LUCIA data along with the pooled Phase 3 datasets to further assess next steps for DURAVYU as a potential treatment for wet AMD.”

Source: [EyePoint third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526456889/eypt-ex99_1.htm)

> “WATERTOWN, Mass., October 19, 2026 (GLOBE NEWSWIRE)”
> “This strategic realignment follows today’s topline readout from the Phase 3 LUCIA study of DURAVYU in wet AMD, which did not meet its primary endpoint of non-inferiority”
> “to conclude the pivotal Phase 3 wet AMD trials early, without full completion of the second year of each trial.”
> “EyePoint plans to prioritize the development of DURAVYU for the potential treatment of DME, which is expected to read out pivotal Phase 3 topline data in the fourth quarter of 2027.”

Source: [EyePoint strategic prioritization announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-ex99_1.htm)

> “In LUCIA, despite demonstrating visual improvement, DURAVYU did not achieve the primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity (BCVA) versus on-label 2 mg aflibercept control.”
> “EyePoint will complete additional analyses of the LUCIA and pooled Phase 3 datasets to further assess next steps for DURAVYU as a potential treatment for wet AMD.”

Source: [EyePoint LUCIA topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm)

<a id="topic-2.1.1-11"></a>

##### Launch

No evidence found.

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Established name, proprietary name, and development code

> “DURAVYU™ (vorolanib intravitreal insert a/k/a EYP-1901)”

Source: [EyePoint investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_2.htm)

<a id="topic-2.1.2.1-2"></a>

###### Therapeutic class and delivery technology

> “Our lead product candidate, DURAVYU™ (a/k/a EYP-1901), is an investigational sustained delivery treatment for vascular endothelial growth factor (VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) with Durasert E™.”

Source: [EyePoint Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526335037/eypt-20260630.htm)

> “A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD”

Source: [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)

<a id="topic-2.1.2.1-3"></a>

###### Manufacturer: EyePoint

> “EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases.”
> “The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-2.1.2.1-4"></a>

###### Sponsor and licensor of vorolanib

> “Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Phase 3 dose: two inserts in one injection

> “The investigational dose for phase 3 trials is 2.7mg (two inserts) administered with one injection.”
> “DURAVYU dosing consists of 2 inserts delivered in a single injection.”
> “1343 µg/insert”

Source: [EyePoint investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_2.htm)

<a id="topic-2.1.2.2-2"></a>

###### Phase 3 dose as registered

| Field | Quoted record |
| --- | --- |
| Experimental arm | “EYP-1901 2686 µg” |
| Route | “Intravitreal Injection” |

Source: [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)

<a id="topic-2.1.2.2-3"></a>

###### Insert composition

> “EYP-1901 intravitreal insert contains vorolanib as the active ingredient and polyvinyl alcohol as an excipient.”

Source: [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)

> “94% drug / 6% matrix”
> “No cold storage required unlike approved biologics; pre-loaded IVT syringe injector”

Source: [EyePoint investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_2.htm)

> “This formulation allows the solid insert to deliver a higher payload of drug (94%) for sustained delivery until the drug is fully released from the insert.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.1.2.2-4"></a>

###### Phase 2 DAVIO 2 dose strengths and applicator configuration

| Dose (μg) | Number of inserts per single applicator | Needle gauge | Insert length (mm) |
| --- | --- | --- | --- |
| “2,060” | “2” | “22” | “8” |
| “3,090” | “3” | “22” | “8” |

Source: [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)

<a id="topic-2.1.2.2-5"></a>

###### Storage conditions in clinical trials

> “EYP-1901 must be stored in a secure place and at controlled room temperature (20°C to 25°C/68°F to 77°F) and in the original container to protect the product from light. Temperature excursions between 15°C to 30°C/59°F to 86°F are acceptable.”

Source: [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Mechanistic classification: type II pan-VEGFR tyrosine kinase inhibitor

> “Our modeling results predict that vorolanib strongly binds intracellularly near the ATP binding regions of VEGFR1, VEGFR2, and VEGFR3 when the VEGFRs are in the DFG-out (inactive) configuration, making vorolanib a type II pan-VEGFR inhibitor.”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11149885/)

<a id="topic-2.1.2.4-2"></a>

###### Prior approval of oral vorolanib outside ophthalmology

> “vorolanib tablets in combination with everolimus were approved in 2023 by China’s National Medical Products Administration for the treatment of advanced renal cell carcinoma”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11149885/)

<a id="topic-2.1.2.4-3"></a>

###### AHFS classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Proposed indication for the planned NDA

> “the submission of a potential FDA New Drug Application for DURAVYU™ for the potential treatment of wet AMD in the first half of 2027”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.1.2.5-2"></a>

###### Population studied in the phase 3 wet AMD trials

> “Trials include approximately 75% treatment-naïve and 25% previously treated patients.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

> “Previously treated or treatment naïve patients with a documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit.”
> “For previously-treated subjects, must have been treated with at least 2 anti-VEGF IVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab, or faricimab) in the previous 6 months for wAMD per standard of care in the study eye prior to the Screening Visit.”

Source: [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)

<a id="topic-2.1.2.5-3"></a>

###### Label scope sought by the sponsor

> “Evaluating every 6-month dosing for potential unlimited redosing label”

Source: [EyePoint investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_2.htm)

<a id="topic-2.1.2.5-4"></a>

###### Other indication in development: diabetic macular edema

> “Randomized, double-masked, aflibercept controlled, non-inferiority trials assessing the efficacy and safety of DURAVYU 2.7mg in patients with active DME.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Receptor-level blockade of VEGF signaling

> “Vorolanib, the active drug in DURAVYU, acts through intracellular binding of all VEGF receptors thereby blocking all VEGF isoforms, the main driver of the proliferation of blood vessels that are the hallmark of wet AMD and DME.”
> “The inhibition of PDGF by vorolanib may provide antifibrotic benefits and the inhibition of IL-6 signaling, by blocking JAK-1, may provide an anti-inflammatory effect.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### ATP-competitive inhibition of VEGFR-1, -2, and -3

> “potently inhibits all 3 VEGFRs (VEGFR-1, -2, and -3; manuscript in preparation) by competing with adenosine triphosphate for binding to the tyrosine kinase domain of VEGFR inside the cell membrane.”
> “Vorolanib would therefore be expected to inhibit most VEGF pathway signaling, perhaps to a greater degree than current anti-VEGF drugs that each target only 1 form of VEGF and leave VEGFRs available to be activated by other forms of VEGF.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-2.1.2.6.1-3"></a>

###### Selectivity against TIE2 compared with other TKIs

> “Vorolanib, sunitinib, and axitinib exhibited pan-VEGFR inhibition and inhibited RTKs associated with pathological angiogenesis. Of the three TKIs, only axitinib potently inhibited TIE2 which is an undesired trait as TIE2 is essential for vascular stability.”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11149885/)

<a id="topic-2.1.2.6.1-4"></a>

###### Sustained delivery through the bioerodible Durasert E insert

> “In this structure, there are no non-erodible polymer layers utilized and the resulting insert consists of bioerodible matrix and the active drug, vorolanib.”
> “By design, the core matrix maintains the drug release before it fully bio-erodes to avoid free-floating drug particles.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.1.2.6.1-5"></a>

###### Class mechanism and differences in receptor selectivity among VEGFR tyrosine kinase inhibitors

> “Tyrosine kinase inhibitors (TKIs) are small molecules that act at the intracellular level to inhibit receptor tyrosine kinase by preventing tyrosine kinase phosphorylation and the downstream signaling cascade.”
> “Notably, TKIs are capable of inhibiting all isoforms of VEGF as well as other receptor tyrosine kinases including fibroblast growth factor receptor and platelet-derived growth factor receptor.”
> “In vitro, individual TKIs differ in their VEGFR-binding affinity, receptor selectivity profiles, and off-target inhibition.”
> “These differences in molecular selectivity may influence not only efficacy and durability but also safety profiles when these agents are applied to ocular tissues via sustained-release platforms.”

Source: [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical: VEGFR2 inhibitory concentration

> “for vorolanib (52nM; 23 ng/mL) and axitinib (0.2nM; 0.07 ng/mL)”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11149885/)

<a id="topic-2.1.2.6.2-2"></a>

###### Preclinical: angiogenesis and melanin binding

> “All three TKIs effectively inhibited angiogenesis in vitro. In vivo, TKIs were more effective at inhibiting VEGF-induced angiogenesis than the anti-VEGF antibody bevacizumab. Of the three TKIs, only sunitinib bound melanin.”

Source: [Bakri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11149885/)

<a id="topic-2.1.2.6.2-3"></a>

###### Preclinical: IL-6 signaling and neuroprotection

> “data showed a reduction in IL-6 activity of more than 50% associated with vorolanib, the active ingredient in DURAVYU, via inhibition of JAK1, suggesting anti-inflammatory properties.”
> “Vorolanib has also demonstrated neuroprotection in an in-vivo model of retinal detachment.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.1.2.6.2-4"></a>

###### Preclinical: time to target tissue concentrations in rabbits

> “Following a single DURAVYU 900 µg dose in Dutch-Belted rabbits, vorolanib reached concentrations exceeding IC50 in the choroid and retina within hours of administration.”

Source: [EyePoint investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_2.htm)

<a id="topic-2.1.2.6.2-5"></a>

###### Preclinical: oral vorolanib in choroidal and retinal neovascularization models

> “Oral X-82 was found to inhibit Matrigel-induced choroidal neovascularization in a rat model.”
> “An oxygen-induced ischemic retinopathy mouse model also showed potent inhibition of retinal neovascularization, with cell culture studies suggesting similar antiangiogenic activity to sunitinib.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Summary: systemic and aqueous humor exposure in DAVIO 2

In the phase 2 DAVIO 2 trial, a single vorolanib insert dose (2,060 µg or 3,090 µg) was given at week 8. Mean plasma vorolanib concentrations were 0.000 pg/mL at week 8 (the visit at which the insert was administered), 23.206 pg/mL (2,060 µg; 46 participants) and 27.121 pg/mL (3,090 µg; 47 participants) at week 20, and 7.733 pg/mL (45 participants) and 10.392 pg/mL (50 participants) at week 56. Mean aqueous humor concentrations at week 20 were 17.426 ng/mL (43 participants) and 25.066 ng/mL (49 participants). Plasma concentrations were reported in picograms per milliliter and aqueous humor concentrations in nanograms per milliliter. Mean plasma concentrations of the main metabolite did not exceed 2.46 pg/mL at any sampled visit.

Source: [ClinicalTrials.gov NCT05381948 API record](https://clinicaltrials.gov/api/v2/studies/NCT05381948)

<a id="topic-2.1.2.6.3-2"></a>

###### Release duration by design

> “Each EYP-1901 insert has been designed to deliver vorolanib into the vitreous humor for at least 9 months.”

Source: [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)

> “Consistent daily dosing with target inhibition for ≥6 months”
> “Full elution of vorolanib before matrix bioerosion; no free-floating drug particles”

Source: [EyePoint investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_2.htm)

<a id="topic-2.1.2.6.3-3"></a>

###### Preclinical release kinetics in rabbits

> “In rabbit studies, the EYP-1901 insert showed a burst in drug release that rapidly resulted in steady-state levels in ocular tissues with an average zero-order drug-release rate of approximately 8% of the total dose per month through 8 months; this was followed by a rapid decrease through 10 months.”

Source: [Wykoff et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11418737/)

<a id="topic-2.1.2.6.3-4"></a>

###### Preclinical ocular and plasma concentrations in rabbits

> “Findings showed that EYP-1901 was able to reach steady state quickly in all locations and this was maintained until depletion of the drug around 240–270 days after insert. The main targets of retina and choroid maintained a VEGFR2 IC50 of above 23 ng/ml through day 240 while plasma and aqueous humor levels were consistently below 23 ng/ml”
> “Based on the insert measurements, the 643 μg insert showed a release rate of 1.73 μg per day while the 2 inserts of 900 μg showed a release rate of 2.33 μg per day”

Source: [Sayed et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11497975/)

<a id="topic-2.1.2.6.3-5"></a>

###### DAVIO 2: plasma vorolanib concentrations (pg/mL) after a single insert dose at week 8

| Visit | 2,060 µg mean | 2,060 µg SD | 3,090 µg mean | 3,090 µg SD |
| --- | --- | --- | --- | --- |
| Week 8 | “0.000” | “0.0000” | “0.000” | “0.0000” |
| Week 20 | “23.206” | “8.8871” | “27.121” | “10.0821” |
| Week 32 | “14.333” | “6.1098” | “19.335” | “7.3783” |
| Week 44 | “10.292” | “5.2086” | “14.180” | “4.9819” |
| Week 56 | “7.733” | “4.9684” | “10.392” | “5.2315” |

Source: [ClinicalTrials.gov NCT05381948 API record](https://clinicaltrials.gov/api/v2/studies/NCT05381948)

<a id="topic-2.1.2.6.3-6"></a>

###### DAVIO 2: aqueous humor vorolanib concentrations (ng/mL) after a single insert dose at week 8

| Visit | 2,060 µg mean | 2,060 µg SD | 3,090 µg mean | 3,090 µg SD |
| --- | --- | --- | --- | --- |
| Week 8 | “0.000” | “0.0000” | “0.000” | “0.0000” |
| Week 20 | “17.426” | “13.7143” | “25.066” | “18.8594” |
| Week 32 | “11.890” | “10.8436” | “19.813” | “15.0833” |

Source: [ClinicalTrials.gov NCT05381948 API record](https://clinicaltrials.gov/api/v2/studies/NCT05381948)

<a id="topic-2.1.2.6.3-7"></a>

###### DAVIO: plasma exposure after 6 months

> “In both patients, these SAEs occurred >6 months after receiving EYP-1901 at a time point when the study drug was undetectable in plasma.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-2.1.2.6.3-8"></a>

###### Pharmacokinetics after repeat dosing every 6 months

No evidence found.

<a id="topic-2.1.2.6.3-9"></a>

###### Vitreous clearance of tyrosine kinase inhibitors and the rationale for sustained release

> “Rapid vitreous clearance of existing VEGF inhibitors limits durability to 1-4 months.”
> “TKIs are small molecules and rapidly cleared from the vitreous.”
> “Combining TKIs with sustained release platforms, such as hydrogel or polyvinyl alcohol, allow for the sustained release of the molecules and the potential for extended durability.”
> “The implant is designed to release vorolanib at near zero order kinetics for 9 months and to be completely bioerodible.”

Source: [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Summary: safety in LUGANO through week 56

Through week 56 of LUGANO, the ocular adverse events in the study eye with the largest absolute differences between vorolanib intravitreal insert 2.7 mg (211 participants) and aflibercept 2 mg (221 participants) were conjunctival haemorrhage (11.4% and 5.0%), vitreous floaters (9.0% and 3.6%), and neovascular age-related macular degeneration (7.1% and 1.4%). Intraocular inflammation (0.5% in each arm) and retinal detachment (0.5% in each arm) were infrequent, and the sponsor reported no cases of insert migration into the anterior chamber, retinal vasculitis, or severe intraocular inflammation. Nine participants (4%) in the vorolanib insert arm lost 15 or more letters from causes attributed by the sponsor to geographic atrophy (6), glaucoma (2), or retinal detachment (1); no participant in the aflibercept arm had such a loss. These data are preliminary and pending final analysis.

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.1.2.7.1-2"></a>

###### FDA-approved prescribing information, contraindications, boxed warnings, and REMS

Not applicable.

<a id="topic-2.1.2.7.1-3"></a>

###### LUGANO: ocular adverse events in the study eye (≥2%) through week 56

| Adverse event | DURAVYU 2.7 mg (n=211) | Aflibercept 2 mg (n=221) |
| --- | --- | --- |
| Conjunctival haemorrhage | “11.4%” | “5.0%” |
| Vitreous floaters | “9.0%” | “3.6%” |
| Neovascular age-related macular degeneration | “7.1%” | “1.4%” |
| Retinal haemorrhage | “4.7%” | “1.8%” |
| Vitreous detachment | “4.7%” | “4.1%” |
| Cataract | “4.3%” | “5.4%” |
| Dry eye | “4.3%” | “6.3%” |
| Posterior capsule opacification | “4.3%” | “2.3%” |
| Intraocular pressure increased | “3.8%” | “3.2%” |
| Visual acuity reduced | “3.8%” | “5.4%” |
| Retinal oedema | “2.8%” | “0.9%” |
| Visual impairment | “2.4%” | “0.0%” |
| Dry age-related macular degeneration | “2.4%” | “3.2%” |
| Eye pain | “2.4%” | “0.9%” |
| Subretinal fluid | “2.4%” | “1.4%” |

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.1.2.7.1-4"></a>

###### LUGANO: selected ocular adverse events in the study eye

| Adverse event | DURAVYU 2.7 mg (N=211) | Aflibercept 2 mg (N=221) |
| --- | --- | --- |
| Intraocular inflammation (IOI) | “0.5%” | “0.5%” |
| Retinal detachment | “0.5%” | “0.5%” |
| Geographic atrophy | “2.4%” | “2.7%” |

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.1.2.7.1-5"></a>

###### LUGANO: adverse events of particular interest and discontinuations

> “AEs of particular interest – all <1% in both arms”
> “All cases of floaters were mild or moderate with no required treatment or impact on vision”
> “Low patient discontinuation rate of 6% through Week 56 in each arm”
> “No study or treatment discontinuations were related to DURAVYU”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

> “No difference in cataracts, elevated intraocular pressure, or intraocular inflammation between study and control group”
> “No observed occurrences of insert migration, anterior chamber opacities, free-floating drug particles, retinal vasculitis, or severe intraocular inflammation (IOI)”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-2.1.2.7.1-6"></a>

###### LUGANO: vision loss of 15 or more letters not attributed to wet AMD

> “9 patients (of 211) lost ≥ 15 letters from non-wet AMD etiologies in DURAVYU arm, driving the endpoint result”
> “Zero patients (of 216) in aflibercept control arm lost ≥15 letters from non-wet AMD etiologies”
> “Geographic atrophy (n=6)”
> “Glaucoma (n=2)”
> “Retinal detachment (n=1)”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.1.2.7.1-7"></a>

###### LUGANO: baseline ocular history of dry AMD and glaucoma in the study eye

| Medical history in study eye | DURAVYU 2.7 mg (n=211) | Aflibercept 2 mg q8W (n=216) |
| --- | --- | --- |
| Dry AMD | “24.6%” | “21.7%” |
| Glaucoma | “11.4%” | “5.9%” |

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.1.2.7.1-8"></a>

###### Phase 2 DAVIO 2: selected ocular adverse events in the study eye through week 56

| Adverse event | Aflibercept 2 mg (54 participants) | EYP-1901 2,060 µg (50 participants) | EYP-1901 3,090 µg (52 participants) |
| --- | --- | --- | --- |
| Endophthalmitis | “2” | “0” | “3” |
| Intraocular pressure increased | “2” | “3” | “2” |
| Vitreous floaters | “1” | “2” | “6” |
| Visual acuity reduced | “3” | “1” | “8” |
| Retinal haemorrhage | “1” | “2” | “6” |

Source: [ClinicalTrials.gov NCT05381948](https://clinicaltrials.gov/study/NCT05381948)

<a id="topic-2.1.2.7.1-9"></a>

###### Phase 1 DAVIO: ocular events not observed after a single dose

> “There were no vitreous floaters, endophthalmitis, retinal detachment, insert migration into the anterior chamber, retinal vasculitis, posterior or anterior segment inflammation, vascular occlusive events, or ischemic optic neuropathy observed throughout the study.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-2.1.2.7.1-10"></a>

###### Oral vorolanib: systemic adverse events in the APEX trial

> “The APEX Trial was stopped prematurely due to gastrointestinal and hepatobiliary AEs associated with oral vorolanib use such as elevated liver enzymes, and due to the fulfillment of the primary endpoint (noninferiority to placebo).”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-2.1.2.7.1-11"></a>

###### Hypersensitivity

> “Vorolanib and the inactive ingredients of EYP-1901 are not known to cause hypersensitivity reactions.”

Source: [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)

<a id="topic-2.1.2.7.1-12"></a>

###### Class labeling for intravitreal VEGF inhibitors (aflibercept 8 mg)

> “Endophthalmitis, retinal detachments, and retinal vasculitis with or without occlusion may occur following intravitreal injections.”
> “Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.”
> “There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors.”

Source: [Regeneron EYLEA HD prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761355s005lbl.pdf)

<a id="topic-2.1.2.7.1-13"></a>

###### Oral vorolanib: timing and reversibility of liver enzyme elevations

> “Most of the elevations occurred within 8–10 weeks of randomisation.”
> “Most commonly, liver enzymes returned to normal within a few weeks after discontinuation of X-82, although some patients required several months to return to baseline.”
> “Importantly, all elevations returned to baseline and there were no accompanying elevations of bilirubin or alkaline phosphatase.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-2.1.2.7.1-14"></a>

###### Oral vorolanib: transaminase elevation on rechallenge and liver function monitoring

> “An asymptomatic 71-year-old woman receiving 100-mg daily had an ALT level 3.1 times the ULN and an AST level 2.7 times the ULN at month 3. X-82 was withheld, and both normalized within 3 weeks. After rechallenging with 100 mg daily, the ALT level rose to 1.6 times the ULN, and the AST level to 1.5 times the ULN. X-82 was discontinued and transaminases normalized.”
> “The transaminase elevations did not appear to be dose related, and thus, it is important to monitor liver function in all patients receiving X-82 regardless of dose.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Older adults: LUGANO baseline age

| Characteristic | DURAVYU 2.7 mg (n=211) | Aflibercept 2 mg q8W (n=216) |
| --- | --- | --- |
| Age (years), mean (SD) | “77.5 (7.52)” | “77.0 (7.61)” |
| Age ≥ 65, n (%) | “202 (95.7)” | “205 (94.9)” |
| Female, n (%) | “136 (64.5)” | “141 (65.3)” |

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.1.2.8-2"></a>

###### Minimum age studied

> “Male or female subjects, ≥50 years of age.”

Source: [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)

<a id="topic-2.1.2.8-3"></a>

###### Pregnancy, lactation, and contraception

> “Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception during the study as outlined in this protocol.”
> “Based on the anti-VEGF mechanism of action for both EYP-1901 and aflibercept the study treatments may pose a risk to human embryofetal development.”

Source: [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)

<a id="topic-2.1.2.8-4"></a>

###### Cardiovascular, bleeding, and metabolic exclusion criteria (phase 2)

> “Uncontrolled blood pressure (defined as systolic >180 mmHg and/or diastolic >100 mmHg), based on the average of three readings taken with the subject in a resting state.”
> “Myocardial infarction within 6 months prior to screening or New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled atrial fibrillation, uncontrolled angina, cardiomyopathy, ventricular arrhythmias or other cardiac conditions which, in the judgment of the investigator, could make the subject inappropriate for entry into this study.”
> “HbA1c greater than 7% at the Screening Visit.”
> “History or presence of bleeding disorders, including platelet disorders, hemorrhage, acquired or hereditary coagulation disorders (including deep vein thrombosis and pulmonary embolisms), acquired or hereditary vascular disorders, stroke, or transient ischemic attack.”

Source: [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Pediatric use, hepatic impairment, and renal impairment

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Vorolanib intravitreal insert

<a id="topic-2.1.2.9.1-1"></a>

###### Protocol restrictions on prior and concomitant therapies (phase 2)

> “Previous use of any systemic anti-VEGF agents or intraocular brolucizumab in the study eye.”
> “Use of oral corticosteroids (prednisone >10 mg/day or equivalent) within 30 days prior to the Screening Visit.”
> “Use of anti-mitotic or anti-metabolite therapy within 30 days or 5 elimination half-lives of the Screening Visit, whichever is longer.”

Source: [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)

<a id="topic-2.1.2.9.1-2"></a>

###### Clinical drug interaction studies

No evidence found.

<a id="topic-2.1.2.9.1-3"></a>

###### Concomitant atorvastatin withheld with oral vorolanib during transaminase elevation

> “An asymptomatic 69-year-old woman receiving 200 mg daily had an ALT level 8.4 times the ULN and an AST level 2.9 times the ULN at month 2. X-82 and atorvastatin were withheld.”
> “By month 3, the ALT level was 1.6 times the ULN and the AST level 1.1 times the ULN, and she was rechallenged with 100 mg of X-82 daily.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Vorolanib intravitreal insert on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Clinical drug interaction studies

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Summary: phase 3 dosing regimen

In LUGANO and LUCIA, all participants received scheduled aflibercept 2 mg from day 1 through week 8. Participants randomized to vorolanib intravitreal insert received 2.7 mg (two inserts in a single injection) at week 8 and were redosed every 6 months (every 24 weeks), with the second dose at week 32 and the third planned dose at week 56, for a total of four doses over the 2-year trials. Supplemental aflibercept was permitted in both arms when protocol criteria were met. EyePoint stated on November 12, 2026, that it will conclude the wet AMD program before completion of the full second year of LUGANO and LUCIA.

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm); [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm); [EyePoint DSMC recommendation announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-ex99_1.htm); [EyePoint third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526456889/eypt-ex99_1.htm)

<a id="topic-2.1.2.10.1-2"></a>

###### Phase 3: dose and redosing interval

> “Patients in the DURAVYU treatment arm will receive an intravitreal injection of DURAVYU every six months, starting at month two of the trial with a total of four injections over the two-year trial.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

> “DURAVYU dosing every 6 months (q24W)”
> “the number of injections includes the DURAVYU injections at Week 8 and Week 32, and all supplemental injections after Week 8 through Week 56”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.1.2.10.1-3"></a>

###### Phase 3: second and third doses

> “As of May 2, 2026, all active patients in the treatment arm have reached the Week 32 visit, during which patients received their second DURAVYU dose. Over 35% of those patients have also received their third planned dose at Week 56.”

Source: [EyePoint DSMC recommendation announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-ex99_1.htm)

<a id="topic-2.1.2.10.1-4"></a>

###### Dose modification

> “Dose modification is not applicable since EYP-1901 and aflibercept are for single-delivery only.”

Source: [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### In-office intravitreal injection

> “DURAVYU is delivered via a standard intravitreal injection in the physician's office, similar to current practice with FDA approved anti-VEGF treatments.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-2.1.2.10.2-2"></a>

###### Pre-loaded applicator and 22-gauge needle (phase 2)

> “The drug delivery system is placed into a one-time-use siliconized needle attached to an applicator delivery system. The drug product is sterilized after packaging and prior to distribution. In subject, the needle is inserted through the pars plana and the insert is injected into the vitreous.”
> “EYP-1901 will be administered to the study eye by a single injection through the pars plana using a pre-loaded applicator with a 22-gauge needle.”

Source: [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)

<a id="topic-2.1.2.10.2-3"></a>

###### Injector performance in phase 1 and further injector development

> “Investigators experienced difficulties with the injector related to the advancement of the plunger as it pushed the 3 inserts (1030 μg each) through the needle.”
> “The injector issues that caused the deviation have been resolved in the subsequent phase II DAVIO 2 trial, and the device continues to be in development.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

> “for a new injector designed for administration of Durasert”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.1.2.10.2-4"></a>

###### Needle gauge and injector used in phase 3

No evidence found.

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercial manufacturing facility and registration batches

> “The 41,000 square foot Good Manufacturing Process (cGMP) compliant commercial manufacturing facility was built to meet U.S. FDA and EMA standards and will support global manufacturing across the Company’s portfolio, including lead pipeline asset, DURAVYU upon potential regulatory approval.”
> “Manufacturing tech transfer of DURAVYU from Watertown to Northbridge began during 2025.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

> “DURAVYU registration batches completed to support anticipated NDA filing”

Source: [EyePoint investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_2.htm)

<a id="topic-2.1.2.11-2"></a>

###### Supply chain for drug substance and injector components

> “We source the active pharmaceutical ingredient (API) vorolanib from one supplier, and various raw materials and components for DURAVYU drug product manufacturing from third-party vendors. Injector and packaging components are purchased from several different vendors with the needles supplied by a third-party supplier.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.1.2.11-3"></a>

###### FDA warning letter concerning the Watertown facility

> “citing alleged violations of cGMP requirements in connection with an FDA inspection at our Watertown facility in February 2024”

Source: [EyePoint Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526335037/eypt-20260630.htm)

<a id="topic-2.1.2.11-4"></a>

###### Anticipated launch preparation and federal pricing programs

> “Prepare for the potential commercial launch of DURAVYU”
> “In order to be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, we must participate in the U.S. Department of Veterans Affairs, (VA), Federal Supply Schedule, (FSS), pricing program.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.1.2.11-5"></a>

###### Distribution channel, specialty distribution, and patient support programs

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Phase 3: aflibercept loading doses before the first vorolanib insert dose

> “Scheduled aflibercept injections from Day 1 through Week 8 were excluded.”
> “After loading doses, 88% of DURAVYU eyes received 2 DURAVYU treatments and 2 or fewer supplemental injections up to Week 56.”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.1.2.12-2"></a>

###### Phase 3: criteria for supplemental aflibercept

> “Phase 3 supplement criteria as defined by protocol include (i) >5 letters loss in vision and ≥75 microns of new fluid and/or (ii) new hemorrhage due to wet AMD”

Source: [EyePoint investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_2.htm)

<a id="topic-2.1.2.12-3"></a>

###### LUGANO: supplemental aflibercept use in the vorolanib insert arm

| Supplement use (DURAVYU 2.7 mg) | Up to week 32 | Up to week 56 |
| --- | --- | --- |
| Supplement-free patients | “76%” | “54%” |
| Patients with 0 or 1 supplement | “96%” | “79%” |
| Patients with 2 or fewer supplements | “99%” | “88%” |

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

> “1.1 average supplemental injection annualized”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

> “94 % of DURAVYU patients received zero or one supplement up to Week 32”
> “This reduction translates to two fewer injections on average in DURAVYU patients versus on-label aflibercept up to Week 56”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-2.1.2.12-4"></a>

###### Phase 2 DAVIO 2: aflibercept co-administration and rescue therapy

> “At Week 8, all subjects will receive a third aflibercept injection and subjects in the EYP-1901 treatment arms will receive the assigned dose of the EYP 1901 intravitreal insert 30 minutes (+/- 10 minutes) following aflibercept injection”
> “Rescue therapy, other than aflibercept, is prohibited.”

Source: [EyePoint Pharmaceuticals DAVIO 2 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/48/NCT05381948/Prot_000.pdf)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Vorolanib intravitreal insert on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Summary: dosing and administration of vorolanib intravitreal insert compared with approved therapies

In the phase 3 program, vorolanib intravitreal insert 2.7 mg is given by in-office intravitreal injection every 6 months after aflibercept loading, and it requires no cold storage. Approved labeling for aflibercept 2 mg recommends monthly injections for 3 months followed by injections every 8 weeks. Aflibercept 8 mg is given monthly for 3 doses followed by every 8 to 16 weeks, with extension to every 20 weeks considered after 1 year of successful response. Faricimab is given monthly for 4 doses followed by one of three regimens with intervals of up to 16 weeks. Ranibizumab 0.5 mg is given monthly, with less frequent regimens described as not as effective. The ranibizumab port delivery system is refilled every 24 weeks but requires surgical implantation in an operating room and carries a boxed warning for endophthalmitis. The sustained-release TKI axitinib intravitreal hydrogel (AXPAXLI) is investigational; its sponsor plans an NDA submission in the fourth quarter of 2026. No head-to-head trials of vorolanib intravitreal insert against aflibercept 8 mg, faricimab, ranibizumab, the port delivery system, or axitinib intravitreal hydrogel were identified; the phase 3 comparator was aflibercept 2 mg every 8 weeks.

Source: [EyePoint investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-ex99_2.htm); [Regeneron EYLEA prescribing information (2024)](https://www.regeneron.com/downloads/eylea_fpi.pdf); [Regeneron EYLEA HD prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761355s005lbl.pdf); [Genentech VABYSMO prescribing information (2026)](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf); [Genentech LUCENTIS prescribing information (2024)](https://www.gene.com/download/pdf/lucentis_prescribing.pdf); [Genentech SUSVIMO prescribing information (2025)](https://www.gene.com/download/pdf/susvimo_prescribing.pdf); [Ocular Therapeutix second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_ex99-1.htm)

<a id="topic-2.1.2.14-2"></a>

###### Sponsor description of approved wet AMD therapies

> “There are multiple short acting effective and safe treatments for wet AMD available on the market, including large molecule anti-VEGF IVT drugs marketed under the brands names Lucentis, Eylea, Eylea HD, Vabysmo, Beovu, and Avastin (off label).”
> “These treatments are injected in a physician’s office either monthly, bi-monthly or in some patients every three to four months, which can cause inconvenience and often leads to reduced compliance and poor outcomes.”
> “The branded drug, SUSVIMO™, a port delivery technology for ranibizumab, was approved by the FDA in 2021 for the treatment of wet AMD and requires an initial surgical placement of the port.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.1.2.14-3"></a>

###### Aflibercept 2 mg: labeled dosing in wet AMD

> “The recommended dose for EYLEA is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 3 months, followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal injection once every 8 weeks (2 months).”
> “Although not as effective as the recommended every 8 week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy.”

Source: [Regeneron EYLEA prescribing information (2024)](https://www.regeneron.com/downloads/eylea_fpi.pdf)

<a id="topic-2.1.2.14-4"></a>

###### Aflibercept 8 mg: labeled dosing in wet AMD

> “The recommended dose for EYLEA HD is 8 mg (0.07 mL of 114.3 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week.”
> “Extended dosing intervals (8 mg once every 20 weeks, +/- 1 week) may be considered after one year of successful response based on visual and anatomic outcomes”

Source: [Regeneron EYLEA HD prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761355s005lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Faricimab: labeled dosing in wet AMD

> “The recommended dose for VABYSMO is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for the first 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to inform whether to give a 6 mg dose via intravitreal injection on one of the following three regimens: 1) Weeks 28 and 44; 2) Weeks 24, 36 and 48; or 3) Weeks 20, 28, 36 and 44.”

Source: [Genentech VABYSMO prescribing information (2026)](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf)

<a id="topic-2.1.2.14-6"></a>

###### Ranibizumab 0.5 mg: labeled dosing in wet AMD

> “LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).”
> “Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses.”

Source: [Genentech LUCENTIS prescribing information (2024)](https://www.gene.com/download/pdf/lucentis_prescribing.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Ranibizumab port delivery system: labeled dosing, surgical requirement, and boxed warning

> “The recommended dose of SUSVIMO (ranibizumab injection) is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO ocular implant with refills administered every 24 weeks (approximately 6 months).”
> “The SUSVIMO ocular implant must be surgically implanted in the eye or removed from the eye (if medically necessary) in an operating room using aseptic technique.”
> “The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab.”

Source: [Genentech SUSVIMO prescribing information (2025)](https://www.gene.com/download/pdf/susvimo_prescribing.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Axitinib intravitreal hydrogel (AXPAXLI): formulation and development status

> “Ocular Therapeutix, Inc. (Ocular Therapeutix) is developing AXPAXLI which utilizes axitinib, a TKI, formulated in a hydrogel and delivered through an intravitreal injection.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

> “New Drug Application (NDA) submission for AXPAXLI in wet AMD planned for Q4 2026, with FDA alignment confirmed in May 2026 Type C meeting minutes.”
> “Following these changes, topline SOL-R results are now expected in the first quarter of 2028.”

Source: [Ocular Therapeutix second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_ex99-1.htm)

<a id="topic-2.1.2.14-9"></a>

###### Axitinib intravitreal hydrogel (AXPAXLI): SOL-1 and SOL-R designs and SOL-1 results

> “The superiority primary endpoint was met with 74.1% of subjects in the AXPAXLI (0.45 mg) arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to the aflibercept (2 mg) arm.”
> “Subjects in the first arm receive a single dose of AXPAXLI (0.45 mg) at Day 1 and are re-dosed at Weeks 24, 48, and 72.”
> “Subjects in the third arm receive a single dose of aflibercept (8 mg) at Day 1 and are re-dosed at Weeks 24, 48, and 72, aligned with the AXPAXLI treatment arm for adequate masking.”

Source: [Ocular Therapeutix first quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/0001393434/000110465926055241/tm2613442d1_ex99-1.htm)

<a id="topic-2.1.2.14-10"></a>

###### Novel retinal delivery therapies: published comparison table

| Product | Mechanism of action | Duration of action | Phase of development |
| --- | --- | --- | --- |
| Vorolanib insert (EYP-1901) | “TKI: inhibition of all isoforms of VEGFR and PDGFR” | “Six months or longer” | “Phase 3” |
| Axitinib hydrogel insert (OTX-TKI) | “TKI: VEGFR-1, VEGFR-2, VEGFR-3 inhibition” | “Six months or longer” | “Phase 3” |
| Ranibizumab port delivery system | “VEGF-A inhibition” | “Up to 24 weeks” | “FDA approved” |
| Tarcocimab tedromer (KSI-301) | “VEGF-A, VEGF-B, PIGF inhibition” | “Up to six months” | “Phase 3” |

Source: [Rowe et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12360407/)

<a id="topic-2.1.2.14-11"></a>

###### Sponsor-described differentiation from other sustained-delivery products

> “Only sustained-delivery TKI with Phase 3 repeat-dose safety”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.1.2.14-12"></a>

###### Head-to-head comparisons with aflibercept 8 mg, faricimab, ranibizumab, the port delivery system, or axitinib intravitreal hydrogel

No evidence found.

<a id="topic-2.1.2.14-13"></a>

###### Axitinib intravitreal hydrogel (OTX-TKI): phase 1b rescue-free proportion and visual acuity at week 52

> “By week 48, 67% of AXPAXLI-treated patients remained rescue-free, but this declined to 33% by week 52, suggesting a waning therapeutic effect near the end of the implant’s duration of action.”
> “There was an 89% reduction in anti-VEGF treatment burden at week 52 in the OTX-TKI arm.”
> “Mean change in BCVA at week 52 was –1.0 (6.0) letters in the OTX-TKI group and +2 (7.2) letters in the aflibercept group.”

Source: [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)

<a id="topic-2.1.2.14-14"></a>

###### Sunitinib microparticle depot (GB-102): dose discontinued for anterior chamber migration and program discontinued

> “After an interim safety analysis, the 2-mg GB-102 dose was discontinued after the initial dose because of a higher incidence of AEs. These AEs included anterior chamber microparticle migration and associated visual impairment and IOP elevation.”
> “The primary end point, median time to first supportive therapy, was 5 months in the 1-mg group. Moreover, 62% and 48% of patients did not require supportive therapy for at least 4 and 6 months, respectively.”
> “At this time, the sponsor has discontinued further investigation of GB-102.”

Source: [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)

<a id="topic-2.1.2.14-15"></a>

###### Independent review: relative position of sustained-delivery platforms and uncertainty about pan-VEGF inhibition

> “Intravitreal agents such as OTX-TKI and EYP-1901 have demonstrated encouraging durability and safety profiles in early-phase trials.”
> “Approaches like suprachoroidal CLS-AX may offer targeted posterior segment drug delivery with reduced anterior segment and systemic exposure.”
> “Among these emerging therapies, platforms combining intravitreal sustained-release technology with pan-VEGF inhibition (eg, EYP-1901, OTX-TKI, CLS-AX) currently appear the most balanced in terms of efficacy, safety, and durability.”
> “However, the clinical value of pan-VEGF inhibition remains uncertain.”

Source: [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)

<a id="topic-2.1.2.14-16"></a>

###### Faricimab phase 3 trials: durability not compared with extended-interval aflibercept

> “one limitation of the TENAYA and LUCERNE trials is the lack of direct comparison of durability of faricimab relative to the standard of care because the comparator in these studies was administered according to a fixed 8-week dosing regimen”
> “The registrational phase 3 trials of faricimab for nAMD were not designed for head-to-head comparison of faricimab’s durability versus aflibercept because extended fixed 12-week or fixed 16-week dosing regimens have not been studied in double-masked phase 3 registrational trials for aflibercept.”

Source: [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/)

<a id="topic-2.1.2.14-17"></a>

###### Aflibercept 8 mg: injections through week 48 and limits of direct comparison with aflibercept 2 mg

> “Patients who completed the week 48 visit received a mean of 6·1 injections in the aflibercept 8q12 group, 5·2 injections in the 8q16 group, and 6·9 injections in the 2q8 group.”
> “The limitations of this study included the inability for direct comparison at several timepoints between the aflibercept 8 mg and 2 mg groups after week 16 due to the different dosing regimens.”

Source: [Lanzetta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38461841/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Summary: definition, etiology, and risk factors

Wet (neovascular) age-related macular degeneration (AMD) is the late-stage form of AMD in which abnormal blood vessels (macular neovascularization, historically called choroidal neovascularization) grow beneath or into the macula. The American Academy of Ophthalmology (AAO) estimates that about 80% of people with AMD have the non-neovascular form, while the neovascular form accounts for most of the severe vision loss. Unmodifiable risk factors are increasing age, Northern European ancestry, and genetic factors; cigarette smoking is the principal modifiable risk factor. In the Global Burden of Disease Study 2021, tobacco accounted for 9.96% of age-standardized disability-adjusted life-years attributed to AMD.

Source: [National Eye Institute (2021)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration); [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp); [GBD 2021 Global AMD Collaborators (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12208786/)

<a id="topic-2.2.1.1-2"></a>

###### Wet AMD as the neovascular late stage of AMD

> “Age-related macular degeneration (AMD) is an eye disease that can blur your central vision. It happens when aging causes damage to the macula”
> “Wet AMD (also called advanced neovascular AMD), is a less common type of late AMD that usually causes faster vision loss. Any stage of dry AMD can turn into wet AMD”
> “but wet AMD is always late stage. It happens when abnormal blood vessels grow in the back of the eye and damage the macula.”

Source: [National Eye Institute (2021)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration)

<a id="topic-2.2.1.1-3"></a>

###### Guideline disease definition and advanced AMD classification

> “Age-related macular degeneration (AMD) is a spectrum of disorders of the macula characterized by one or more of the following:”
> “Advanced AMD (AREDS category 4) is characterized by one or more of the following (in the absence of other causes) in one eye:”
> “Macular neovascularization (MNV) historically referred to as CNV and includes the following:”
> “Although an estimated 80% of patients with age-related macular degeneration (AMD) have non-neovascular or atrophic AMD, the neovascular form is responsible for most of the severe vision loss associated with AMD.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.1-4"></a>

###### Risk factors: age, ancestry, genetics, and smoking

> “The main unmodifiable risk factors for the development of advanced AMD are increasing age, Northern European ancestry, and genetic factors. Although a number of modifiable risk factors have been investigated, cigarette smoking is the main one that has been consistently identified in”
> “Smoking significantly increases the risk of AMD and there appears to be a dose-response”
> “the risk of developing AMD in individuals who have not smoked for more than 20 years is comparable to the risk in nonsmokers.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.1-5"></a>

###### Risk factors: patient-facing summary

> “Your risk for AMD increases as you get older. People age 55 and older are more likely to have AMD. The risk for AMD is also higher for people who:”
> “Have a family history of AMD”
> “Are Caucasian”
> “Smoke”

Source: [National Eye Institute (2021)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration)

<a id="topic-2.2.1.1-6"></a>

###### Tobacco-attributable burden of AMD vision impairment

> “The global contribution of tobacco to age-standardised DALYs decreased by 20%, declining from 12·45% (95% UI 7·73–17·37) in 1990 to 9·96% (6·12–14·06) in 2021.”

Source: [GBD 2021 Global AMD Collaborators (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12208786/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Wet age-related macular degeneration

<a id="topic-2.2.1.2.1-1"></a>

###### Summary: incidence

In a Bayesian meta-analysis of cohort studies in populations of European ancestry, the annual incidence of neovascular AMD in White US adults aged 50 years or older was 1.8 per 1,000, and the incidence of any late AMD was 3.5 per 1,000 (about 293,000 new cases per year). A US cost-benefit analysis estimated 168,400 new-onset neovascular AMD cases in 2018. In the Beaver Dam Eye Study (3,917 participants), the 15-year cumulative incidence of exudative AMD was 4.4% in participants aged 75 years or older at baseline and 0.4% in those aged 43 to 54 years.

Source: [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/); [Brown et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32681907/); [Klein et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17270675/)

<a id="topic-2.2.1.2.1-2"></a>

###### Annual incidence in White US adults: meta-analysis

> “Annual incidence (estimated from prevalence) of late AMD in American whites was 3.5 per 1000 aged ≥50 years (95% credible interval 2.5, 4.7 per 1000), equivalent to 293 000 new cases in American whites per year (95% credible interval 207 000, 400 000). Incidence rates approximately quadrupled per decade in age. Annual incidence GA rates were 1.9 per 1000 aged ≥50 years, NVAMD rates were 1.8 per 1000.”

Source: [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/)

<a id="topic-2.2.1.2.1-3"></a>

###### New-onset neovascular AMD cases in the United States, 2018

> “168,400 estimated 2018 U.S. patients with new-onset NVAMD.”

Source: [Brown et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32681907/)

<a id="topic-2.2.1.2.1-4"></a>

###### Beaver Dam Eye Study: 15-year cumulative incidence

> “The 15-year cumulative incidence was 14.3% for early AMD (the presence of either soft indistinct drusen or the presence of pigmentary abnormalities together with any type of drusen) and 3.1% for late AMD (presence of exudative AMD or geographic atrophy).”
> “Individuals > or = 75 years of age at baseline had significantly (P<0.01) higher 15-year incidences of the following characteristics than people 43 to 54 years of age: larger drusen (125 mum in diameter, 24.1% vs 10.6%), soft indistinct drusen (18.7% vs 6.5%), retinal pigmentary abnormalities (20.2% vs 3.7%), exudative macular degeneration (4.4% vs 0.4%), and pure geographic atrophy (3.2% vs 0%).”

Source: [Klein et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17270675/)

<a id="topic-2.2.1.2.1-5"></a>

###### Neovascular AMD in the fellow eye: untreated cohorts

> “Neovascular AMD developed in the fellow eye in 12.2% of patients by 12 months and in 26.8% by 4 years.”

Source: [Wong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17675159/)

<a id="topic-2.2.1.2.1-6"></a>

###### Progression to advanced AMD in the fellow eye

> “In the AREDS, the risk of progression for patients with advanced AMD in one eye to an advanced stage in the fellow eye ranged from 35% to 50% at 5 years, depending largely on the phenotype in the better eye.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.2.1-7"></a>

###### Annual incidence and number of new neovascular AMD cases in White US adults

> “The corresponding rates for GA and NVAMD are 1.9 per 1000 (95% credible interval 1.3, 2.8) and 1.8 per 1000 (95% credible interval 1.2, 2.5), respectively (Table 3).”
> “This corresponds to approximately 293 000 new cases of late AMD each year (95% credible interval 207 000, 400 000), and 160 000 (95% credible interval 107 000, 234 000) and 148 000 (95% credible interval 103 000, 207 000) for GA and NVAMD, respectively.”
> “Although our overall estimates of NVAMD incidence are high (owing to the inclusion of those at older ages, especially in women), this does not reflect the number in need of treatment.”
> “Of note, the inclusion of older ages in our estimates may include a large number who are unwilling or too frail to undergo treatment.”

Source: [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/)

<a id="topic-2.2.1.2.1-8"></a>

###### Neovascular AMD incidence by age: 65 years or older and 80 years or older

> “In those aged 65 years and older the annual incidence rate for late AMD is 7.8 per 1000 (95% credible interval 5.5, 10.6), 4.3 per 1000 for GA (95% credible interval 2.9, 6.2), and 3.9 per 1000 for NVAMD (95% credible interval 2.7, 5.5).”
> “In those aged 80 years and older the annual incidence rates per 1000 are 19.4 (95% credible interval 13.8, 26.2), 10.9 (95% credible interval 7.2, 16.1), and 9.9 (95% credible interval 6.8, 14.0), respectively.”
> “A meta-analysis of incidence studies showed that the incidence rate for late AMD triples per decade increase in age (rate ratio 2.9; 95% credible interval 2.6, 3.2, Table 2).”
> “Although late AMD incidence increases log-linearly with age, the absolute number of incident cases of late AMD decreases beyond the age of about 85 years because of increased mortality.”

Source: [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/)

<a id="topic-2.2.1.2.1-9"></a>

###### Neovascular AMD incidence by sex

> “Incidence rates for late AMD were 38% higher in women than in men (rate ratio 1.4, 95% credible interval 1.1, 1.8).”
> “For all age groups (except the youngest), women have a slightly higher annual incidence rate of late AMD (4 per 1000, 95% credible interval 2.3, 6.6) than men (2.4 per 1000, 95% credible interval 1.4, 4.2; Table 3).”
> “In those aged 65 years and older the incidence rates of NVAMD within each 5-year age group are higher in women than in men.”
> “Under 70 years of age the number of incident cases is similar in men and women.”

Source: [Rudnicka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25857680/)

<a id="topic-2.2.1.2.1-10"></a>

###### Fellow-eye incidence: effect of outlier studies

> “These cumulative incidence rates were influenced by significant heterogeneity in the studies caused by outliers.”
> “If outliers were not included in the analysis, the 12-month incidence rate changed considerably, from 12.2% to 8.1% (95% CI, 4.9-11.9).”
> “Excluding these outliers from the analysis reduced the 12-month incidence rate changes considerably, from 12.2% to 8.1% (95% CI, 4.9%-11.9%), which is lower than the approximately 12% per year rate reported by other single studies in the literature.”

Source: [Wong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17675159/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Wet age-related macular degeneration

<a id="topic-2.2.1.2.2-1"></a>

###### Summary: prevalence

In a Bayesian meta-regression for 2019 using CDC Vision and Eye Health Surveillance System data, an estimated 1.49 million US adults aged 40 years or older (crude prevalence 0.94%) had late-stage AMD (choroidal neovascularization and/or geographic atrophy) and 18.34 million had early-stage AMD. The 2004 Eye Diseases Prevalence Research Group estimate was 1.75 million US adults with neovascular AMD and/or geographic atrophy (1.47%). No recent US estimate specific to the neovascular subtype was retrieved. Globally, the pooled prevalence of late AMD in people aged 45 to 85 years was 0.37% and of any AMD 8.69%, with 196 million people projected to have AMD in 2020 and 288 million in 2040.

Source: [Rein et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9634594/); [Friedman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15078675/); [Wong et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25104651/)

<a id="topic-2.2.1.2.2-2"></a>

###### United States, 2019: early- and late-stage AMD

> “For 2019, we estimated that there were 18.34 million people 40 years and older (95% uncertainty interval [UI], 15.30-22.03) living with early-stage AMD, corresponding to a crude prevalence rate of 11.64% (95% UI, 9.71-13.98). We estimated there were 1.49 million people 40 years and older (95% UI, 0.97-2.15) living with late-stage AMD, corresponding to a crude prevalence rate of 0.94% (95% UI, 0.62-1.36).”
> “late-stage (defined as choroidal neovascularization and/or geographic atrophy in either eye)”

Source: [Rein et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9634594/)

<a id="topic-2.2.1.2.2-3"></a>

###### United States, 2000: neovascular AMD and/or geographic atrophy

> “The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy.”

Source: [Friedman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15078675/)

<a id="topic-2.2.1.2.2-4"></a>

###### United States: guideline summary and projection

> “In 2019, there were an estimated 20 million individuals in the United States with AMD; of these, 18.34 million had early stages of AMD and 1.49 million had late stages of AMD.”
> “the prevalence of AMD in the United States is anticipated to increase to 22 million by the year 2050, whereas the global prevalence is expected to increase to 288 million by the year 2040.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.2.2-5"></a>

###### Global prevalence: meta-analysis of 39 population-based studies

> “Analysis of 129,664 individuals (aged 30-97 years), with 12,727 cases from 39 studies, showed the pooled prevalence (mapped to an age range of 45-85 years) of early, late, and any age-related macular degeneration to be 8.01% (95% CrI 3.98-15.49), 0.37% (0.18-0.77), and 8.69% (4.26-17.40), respectively.”
> “The projected number of people with age-related macular degeneration in 2020 is 196 million (95% CrI 140-261), increasing to 288 million in 2040 (205-399).”

Source: [Wong et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25104651/)

<a id="topic-2.2.1.2.2-6"></a>

###### Global vision impairment due to AMD, 1990 to 2021 and forecast to 2050

> “Globally, the number of individuals with vision impairment due to AMD more than doubled, rising from 3·64 million (95% uncertainty inverval [UI] 3·04–4·35) in 1990 to 8·06 million (6·71–9·82) in 2021.”
> “By 2050, the number of individuals affected by AMD is projected to increase from 3·40 million males (95% UI 2·81–4·17) in 2021 to 9·02 million (5·72–14·20) and from 4·66 million females (3·88–5·65) to 12·32 million (8·88–17·08).”

Source: [GBD 2021 Global AMD Collaborators (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12208786/)

<a id="topic-2.2.1.2.2-7"></a>

###### Late-stage AMD prevalence by sex and by race and ethnicity, United States 2019

> “The race and ethnicity- and age-standardized rate of late-stage AMD for women (0.94%; 95% UI, 0.57-1.43) was nearly identical to that for men (0.95%; 95% UI, 0.56-1.43).”
> “The gender- and age-standardized rate of late AMD for non-Hispanic White individuals 40 years and older was 1.03% (95% UI, 0.65-1.52).”

Source: [Rein et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9634594/)

| Group | Prevalence count, in millions (95% UI) | Prevalence rate, % (95% UI) |
| --- | --- | --- |
| Female | “0.88 (0.53-1.35)” | “0.94 (0.57-1.43)” |
| Male | “0.60 (0.36-0.91)” | “0.95 (0.56-1.43)” |
| Total | “1.49 (0.97-2.15)” | “0.94 (0.62-1.36)” |
| Hispanic | “0.05 (0.02-0.10)” | “0.38 (0.16-0.79)” |
| Non-Hispanic Black | “0.09 (0.05-0.14)” | “0.65 (0.37-1.03)” |
| Non-Hispanic White | “1.25 (0.78-1.86)” | “1.03 (0.65-1.52)” |
| Non-Hispanic other race | “0.09 (0.04-0.18)” | “1.02 (0.44-1.99)” |

Source: [Rein et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9634594/)

<a id="topic-2.2.1.2.2-8"></a>

###### Late-stage AMD prevalence by state, United States 2019

> “Age-, gender-, and race and ethnicity- standardized prevalence for those 40 years or older ranged from a low of 0.61% (95% UI, 0.40-0.88) in Hawaii to a high of 1.16% (95% UI, 0.76-1.69) in North Dakota”
> “We also estimated substantial variation in the prevalence of both early- and late-stage AMD at the state and county level, even after accounting for differences in demographics.”

Source: [Rein et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9634594/)

<a id="topic-2.2.1.2.2-9"></a>

###### Global prevalence of the neovascular and geographic atrophy subtypes, by ethnicity

> “Eight (21%) of the 39 studies provided information on geographic atrophy and neovascular subtypes.”
> “Subgroup analysis showed similar overall prevalence of geographic atrophy (0·44%, 95% CrI 0·15–1·36) and neovascular age-related macular degeneration (0·46%, 0·18–1·08).”
> “Europeans had a higher prevalence of geographic atrophy (1·11%, 95% CrI 0·53–2·08) than Africans (0·14%, 0·04–0·45), Asians (0·21%, 0·04–0·87), and Hispanics (0·16%, 0·05–0·46).”

Source: [Wong et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25104651/)

<a id="topic-2.2.1.2.2-10"></a>

###### Neovascular AMD as a share of prevalent late-stage AMD

> “Although neovascular AMD accounts for only two thirds of prevalent late-stage cases, it is responsible for over 80% of legal blindness due to AMD.”

Source: [Wong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17675159/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Summary: natural history and mortality

In a meta-analysis of 53 studies including 4,362 participants with untreated neovascular AMD, mean visual acuity loss was 1 line at 3 months, 2.7 lines at 12 months, and 4 lines at 24 months; severe vision loss (more than 6 lines) occurred in 21.3% at 6 months and 41.9% by 3 years, and the proportion with visual acuity worse than 20/200 rose from 19.7% at baseline to 75.7% by 3 years. In the sham arm of the MARINA trial, 62.2% of participants lost fewer than 15 letters at 12 months and mean visual acuity decreased by 10.4 letters. The AAO attributes nearly 90% of AMD-related severe visual acuity loss (20/200 or worse) to the neovascular form. The AAO cites Salisbury Eye Study data linking visual acuity loss to activities of daily living and mortality risk, and a US cost-utility model estimated that 11 years of anti-VEGF therapy averts a 1.0 year-of-life loss.

Source: [Wong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17675159/); [Rosenfeld et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17021318/); [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp); [Brown et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32565050/)

<a id="topic-2.2.1.3-2"></a>

###### Untreated neovascular AMD: systematic review and meta-analysis

> “Four thousand three hundred sixty-two untreated neovascular AMD patients from published interventional studies.”
> “Mean baseline VA among study patients was 0.64 logarithm of the minimum angle of resolution (logMAR) (approximately 20/87 Snellen). The mean VA change in logMAR progressed from 0.1 (1 line lost) at 3 months to 0.3 (2.7 lines lost) after 12 months and 0.4 (4 lines lost) after 24 months. The proportion of patients who developed severe vision loss (>6 lines) from baseline increased from 21.3% at 6 months to 41.9% by 3 years. The proportion of patients with VA worse than logMAR 1.0 (20/200 Snellen) increased from 19.7% at baseline to 75.7% by 3 years.”
> “A doubling of the visual angle of presenting VA may be expected to occur in the year after initial presentation in eyes with untreated neovascular AMD.”

Source: [Wong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17675159/)

<a id="topic-2.2.1.3-3"></a>

###### Sham-injection arm of the MARINA trial

> “At 12 months, 94.5% of the group given 0.3 mg of ranibizumab and 94.6% of those given 0.5 mg lost fewer than 15 letters, as compared with 62.2% of patients receiving sham injections (P<0.001 for both comparisons).”
> “Mean increases in visual acuity were 6.5 letters in the 0.3-mg group and 7.2 letters in the 0.5-mg group, as compared with a decrease of 10.4 letters in the sham-injection group (P<0.001 for both comparisons).”

Source: [Rosenfeld et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17021318/)

<a id="topic-2.2.1.3-4"></a>

###### Contribution of neovascular AMD to severe vision loss

> “Overall, AMD is responsible for an estimated 46% of cases of severe visual loss (visual acuity [VA] 20/200 or worse) in people over age 40 in the United States.”
> “the neovascular form is responsible for nearly 90% of the severe VA loss (20/200 or worse) from AMD because of its natural history.”
> “Severe VA loss occurs more slowly in patients with GA than in patients with neovascular AMD.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.3-5"></a>

###### Visual acuity loss, activities of daily living, and mortality

> “The Salisbury Eye Study reported that VA loss adversely affected activities of daily living, which subsequently increased mortality risk in older adults. Further calculations estimated that treating AMD with anti-VEGF agents saves 1 to 2 years of life.”
> “Patients can be informed that while central visual loss is common, total visual loss is extremely rare.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.3-6"></a>

###### Modeled year-of-life loss without treatment

> “Eleven-year therapies saved a 1.0 year-of-life loss without treatment from the 11.0-year life expectancy.”

Source: [Brown et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32565050/)

<a id="topic-2.2.1.3-7"></a>

###### Long-term course after anti-VEGF treatment: atrophy and fibrosis

> “Long-term follow-up studies have identified that the gains made in the first 2 years are not maintained in the long term238. In many instances, this loss can be attributed to under-treatment for a variety of reasons, including inability to access ongoing regular treatment, inappropriate treatment protocols and the burden of treatment for the clinician and patient. Besides patients dropping out of treatment, evidence shows that atrophy and fibrosis are important causes of vision loss despite good early results13.”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

<a id="topic-2.2.1.3-8"></a>

###### Untreated neovascular AMD: proportion in each visual acuity loss stratum over time

> “The percentage of patients with severe loss of vision (at least 6 lines of VA loss from the baseline visit) increased from 19.8% (14 studies with 1235 patients) at 6 months to 43.3% (9 studies with 743 patients) by 3 years.”
> “Likewise, the proportion losing fewer than 3 lines decreased from 65.0% to 43.6% over the same period (Table 5).”
> “The proportion of patients losing between 3 and 6 lines at 3 months was 14.1%. This percentage peaked at 27.0% by 1 year and decreased to 18.2% at the 3-year time point.”

Source: [Wong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17675159/)

<a id="topic-2.2.1.3-9"></a>

###### Untreated neovascular AMD: progression to visual acuity worse than 20/200

> “In 19.7%, VA was worse than 20/200 (legal blindness) at study inception, and this proportion increased to 50.3% by 3 months and to 77.6% by 3 years”
> “For example, at the 3-month time point the lower range of the confidence interval (CI) around the proportion of patients with vision worse than 20/200 was 26.2%.”
> “The proportion of patients whose VA worsened (defined generally as any deterioration from baseline) increased from 45.0% at 3 months to 81.1% by 2 years (Fig 3).”

Source: [Wong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17675159/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Macular neovascularization subtypes: consensus nomenclature

> “Type 3 neovascularization is to be used when the vascular complex originates in the retina. Type 1 neovascularization is applied when the vessels originate from the choroid and remain under the RPE. Type 2 neovascularization is denoted if neovascularization that originates in the choroid breaks through the RPE to reach the subretinal space.”

Source: [Spaide et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11559632/)

<a id="topic-2.2.1.4-2"></a>

###### Macular neovascularization subtypes and their consequences: guideline

> “Type 1 MNV: a neovascular complex located in the sub-RPE space originating from the choroid through a defect in Bruch’s membrane”
> “Type 2 MNV: a neovascular complex located in the subretinal space above the RPE originating from the choroid”
> “Type 3 MNV: pathologic angiogenesis originating from the deep retinal capillary plexus and extending to the outer retina (historically referred to as retinal angiomatous proliferation)”
> “Macular neovascularization can lead to the following:”
> “Subretinal fibrosis (formerly known as disciform scar)”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.4-3"></a>

###### VEGF as a mediator of angiogenesis and vascular permeability

> “VEGF (Vascular endothelial growth factor): A significant mediator in the process of angiogenesis and increased vascular permeability and inflammation. It has been identified in neovascularization related to both diabetic retinopathy and AMD. In animal models, the introduction of VEGF has initiated the cascade of neovascularization seen in AMD.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.4-4"></a>

###### Proposed signaling pathway from lipoprotein debris to VEGF-driven MNV

> “7-Ketocholesterol is thought to activate microglia to release cytokines, such as TNF, which mediates VEGF expression in RPE cells and its release preferentially from the basal aspects147. It has been further proposed that the secreted VEGF promotes choroidal endothelial cell activation and migration, potentially by interactions with integrins in ECM components148 and by activating GTPases, namely Rac1 (REF.145).”
> “Furthermore, the generated ROS presumably also diminish the RPE barrier integrity and permit secreted VEGF entry into the retina, which promotes choroidal endothelial cell migration, proliferation and eventually MNV formation149.”
> “The conversion of non-exudative MNV to exudative MNV is likely to be a major disease transition point in neovascular AMD.”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Summary: diagnosis

The AAO Preferred Practice Pattern describes diagnosis based on history (metamorphopsia, decreased vision, scotoma), examination including stereoscopic biomicroscopy of the macula, and imaging. Optical coherence tomography (OCT) is described as important for detecting subretinal and intraretinal fluid and for monitoring response to therapy; fluorescein angiography is indicated to detect and characterize macular neovascularization, and OCT angiography had a pooled sensitivity of 0.87 and specificity of 0.97 for detecting macular neovascularization in a meta-analysis cited by the guideline.

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.5-2"></a>

###### Initial evaluation: history and examination

> “The initial evaluation of a patient with signs and symptoms suggestive of AMD includes all features of the comprehensive adult medical eye evaluation,274 with particular attention to those aspects relevant to AMD.”
> “Binocular slit-lamp biomicroscopy of the ocular fundus is often necessary to detect subtle clinical signs of MNV. These include small areas of hemorrhage, hard exudates, subretinal fluid, macular edema, subretinal fibrosis, or pigment epithelial elevation.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.5-3"></a>

###### Optical coherence tomography

> “Optical coherence tomography is important in diagnosing and managing AMD, particularly with respect to determining the presence of subretinal and intraretinal fluid and in documenting the degree of retinal thickening.”
> “It may reveal the presence of fluid that is not apparent on biomicroscopy alone. It also helps in evaluating the response of the retina and RPE to therapy by allowing structural changes to be followed accurately.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.5-4"></a>

###### Optical coherence tomography angiography

> “A meta-analysis of OCTA for detection of MNV revealed a sensitivity of 0.87 and specificity of 0.97.”
> “Optical coherence tomography angiography may detect subclinical MNV, which needs close monitoring and not treatment.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.5-5"></a>

###### Fluorescein angiography: indications and risks

> “To detect the presence of and determine the extent, type, size, and location of MNV.”
> “If MNV is suspected on the basis of new symptoms or ocular findings, fluorescein angiography should be performed and interpreted expeditiously by an individual experienced in managing patients with neovascular AMD.”
> “Even death from anaphylaxis has been reported (approximately 1 in 200,000 patients).”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.5-6"></a>

###### Multimodal imaging: role of fluorescein angiography and OCT

> “Although ophthalmoscopy might be sufficient for a basic diagnosis of AMD, fluorescein angiography is the gold standard for detecting and differentiating MNV. Furthermore, OCT imaging is particularly suitable for monitoring the disease, especially in the context of anti-VEGF therapy.”
> “On OCT, exudative activity typically presents with intraretinal and/or subretinal fluid.”

Source: [Fleckenstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12878645/)

<a id="topic-2.2.1.5-7"></a>

###### Patient-facing description of diagnostic testing

> “Eye doctors can check for AMD as part of a comprehensive dilated eye exam.”
> “Your doctor may also recommend doing a test called optical coherence tomography (OCT).”

Source: [National Eye Institute (2021)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Visual symptoms: metamorphopsia, central blur, and scotomas

> “In late AMD (wet or dry type), many people notice that straight lines start to look wavy or crooked. You may also notice a blurry area near the center of your vision. Over time, this blurry area may get bigger or you may see blank spots. Colors may also seem less bright than before, and you may have more trouble seeing in low lighting.”
> “Straight lines looking wavy is a warning sign for late AMD.”

Source: [National Eye Institute (2021)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration)

<a id="topic-2.2.1.6-2"></a>

###### Visual symptoms: guideline symptom history

> “Metamorphopsia”
> “Decreased vision”
> “Scotoma”
> “Photopsia”
> “Difficulties in dark adaptation”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.6-3"></a>

###### Psychiatric symptoms: depressive symptoms at presentation for anti-VEGF therapy

> “In a clinic-based cohort of 547 patients with nAMD who presented for treatment”
> “The prevalence of depressive symptoms was 42.04% and 31.78% as per the CES-D-10 and MHI scales, respectively.”

Source: [Vu et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32981226/)

<a id="topic-2.2.1.6-4"></a>

###### Psychiatric symptoms: depression and Charles Bonnet syndrome in guideline counseling

> “Depression and visual hallucinations (Charles Bonnet syndrome) frequently accompany severe central vision loss. Patients who have Charles Bonnet syndrome and their family members should be informed that visual symptoms are not unusual and do not represent a sign of psychosis or mental deterioration.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.6-5"></a>

###### Visual hallucinations: Charles Bonnet syndrome prevalence meta-analysis

> “We identified 18 studies with data on >4303 patients with AMD. We found an overall prevalence of CBS of 15.8% (95% confidence interval: 11.0%-21.2%). When looking at consecutively recruited patients with neovascular AMD from the clinic, prevalence of CBS was 7.2% (95% confidence interval: 4.3%-10.6%).”

Source: [Niazi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31654492/)

<a id="topic-2.2.1.6-6"></a>

###### Visual hallucinations: Charles Bonnet syndrome in a Danish neovascular AMD cohort

> “Twenty-five (8.3%) patients of 300 had hallucinations attributable to CBS.”

Source: [Singh and Sørensen (2012)](https://pubmed.ncbi.nlm.nih.gov/21106047/)

<a id="topic-2.2.1.6-7"></a>

###### Psychiatric symptoms: mental health scores by visual acuity

> “When stratified by VA, patients with a habitual VA of 20/200 or worse scored the lowest on mental health subscales scores: median of 43.8 (IQR: 31–62). Patients with a VA of 20/20 scored the highest: 87.5 (IQR: 81–94).”

Source: [Fonteh et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526530/)

<a id="topic-2.2.1.6-8"></a>

###### Functional symptoms: reading, face recognition, and driving

> “AMD doesn’t cause complete blindness, but losing your central vision can make it harder to see faces, read, drive, or do close-up work like cooking or fixing things around the house.”

Source: [National Eye Institute (2021)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration)

<a id="topic-2.2.1.6-9"></a>

###### Functional symptoms: impaired activities of daily living at presentation

> “The prevalence of impaired basic, instrumental and total ADL was 37.76%, 67.82% and 39.59%, respectively.”
> “Depressive symptoms [OR 2.08, 95% CI (1.08–4.00)], the presence of any disability [OR 3.16, 95% CI (1.64–0.07)] and never driving [OR 4.00, 95% CI (1.60–10.00)] were also positively associated with total ADL impairment.”

Source: [Van Vu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11156866/)

<a id="topic-2.2.1.6-10"></a>

###### Functional symptoms: falls

> “Loss of VA increases the risk of frequent falls.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

> “About 10% of prevalent patients had a fall/fracture claim over 12 months of follow-up.”

Source: [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)

Additional sources: [Leandro et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28829845/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Summary: long-term morbidity

In the CATT trial, 480 of 1,059 eyes (45.3%) receiving anti-VEGF therapy developed scar by 2 years (fibrotic scar 24.7%, nonfibrotic scar 20.6%). A 2026 review reports that 20% to 67% of treated participants develop macular fibrosis within 2 to 7 years. In a US TriNetX cohort of 92,849 people with neovascular AMD, 21.24% had a diagnosis of visual impairment, the highest proportion among the single ocular diseases analyzed. Globally, 1.85 million people were blind and 6.23 million had moderate or severe vision impairment due to AMD in 2020. In a French nationwide cohort of 1,662 people with incident treated neovascular AMD, the condition was associated with a 19% increase in the risk of disability in activities of daily living and of mood disorders.

Source: [Daniel et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3943618/); [Xu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42259444/); [Chu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11543832/); [Vision Loss Expert Group of the Global Burden of Disease Study (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11269688/); [Delcourt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13460392/)

<a id="topic-2.2.1.7-2"></a>

###### Scar formation during anti-VEGF therapy: CATT

> “Scar developed in 480 of 1059 eyes (45.3%) by 2 years.”
> “Fibrotic scars developed in 24.7% of eyes, and nonfibrotic scars developed in 20.6% of eyes.”

Source: [Daniel et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3943618/)

<a id="topic-2.2.1.7-3"></a>

###### Macular fibrosis as an end-stage complication

> “Macular subretinal fibrosis represents the end-stage complication of neovascular age-related macular degeneration (nAMD). Despite the widespread use of anti-VEGF therapy, between 20 and 67% of nAMD patients develop this sight-threatening condition within 2 to 7 years, making fibrosis one of the main reasons responsible for anti-VEGF resistance and irreversible visual loss.”

Source: [Xu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42259444/)

<a id="topic-2.2.1.7-4"></a>

###### Visual impairment among people with neovascular AMD in the United States

> “The prevalence of having a visual impairment which is composed of the sum of patients with low vision and blindness was highest among neovascular AMD patients at 21.24% and lowest among DR patients at 12.63% (Table 1).”

Source: [Chu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11543832/)

<a id="topic-2.2.1.7-5"></a>

###### AMD as a cause of blindness in the United States

> “The leading cause of blindness among white persons was age-related macular degeneration (54.4% of the cases), while among black persons, cataract and glaucoma accounted for more than 60% of blindness.”

Source: [Congdon et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15078664/)

<a id="topic-2.2.1.7-6"></a>

###### Global blindness and moderate or severe vision impairment due to AMD, 2020

> “In 2020, 1.85 million (95%UI: 1.35 to 2.43 million) people were estimated to be blind due to AMD, and another 6.23 million (95%UI: 5.04 to 7.58) with MSVI globally. High-income countries had the highest number of individuals with AMD-related blindness (0.60 million people; 0.46 to 0.77).”

Source: [Vision Loss Expert Group of the Global Burden of Disease Study (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11269688/)

<a id="topic-2.2.1.7-7"></a>

###### Disability and mood disorders after treated neovascular AMD: French nationwide cohort

> “During the study period, 1662 cases of incident nAMD were identified. After adjustment for age, sex, Charlson comorbidity index and number of drugs, nAMD was significantly associated with the occurrence of ADL disability (Hazard ratio (HR): 1.19, 95% confidence interval (CI): 1.08–1.30; p = 0.0002) and of mood disorders (HR: 1.19, 95%CI: 1.07–1.32; p = 0.002). Associations with falls, fractures and head trauma were not statistically significant.”

Source: [Delcourt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13460392/)

<a id="topic-2.2.1.7-8"></a>

###### Irreversible vision loss after interrupted anti-VEGF therapy

> “When treatments are interrupted, discontinued, or both, irreversible vision loss can occur.”
> “Outside of clinical trials, in clinical practice, patients with neovascular AMD who became LTFU during anti-VEGF therapy experienced significant visual decline at the return visit that persisted despite the normalization of retinal anatomic features with the resumption of care.”
> “Interruptions to anti-VEGF treatment led to irreversible vision loss that could not be recovered with the resumption of care.”

Source: [Khurana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36858288/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Wet age-related macular degeneration

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Summary: humanistic burden

Time trade-off utility values in participants with AMD decline with visual acuity in the better-seeing eye, from 0.89 at 20/20 to 20/25 to 0.40 at counting fingers to light perception (80 participants); participants in the lowest visual acuity group were willing to trade 60% of remaining lifetime for perfect vision. National Eye Institute Visual Function Questionnaire-25 mental health subscale scores were lowest in participants with visual acuity of 20/200 or worse (median 43.8). Among 130 participants in a Norwegian survey, 33.1% reported stress in the week before an injection and 54.6% described the injection as uncomfortable.

Source: [Brown et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10636413/); [Fonteh et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526530/); [Reitan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10226541/)

<a id="topic-2.2.1.8.1-2"></a>

###### Utility values by visual acuity in the better-seeing eye

| Visual acuity in the better-seeing eye | Time trade-off utility (95% CI) |
| --- | --- |
| Group 1: 20/20 to 20/25 | “0.89 (95% CI, 0.82-0.96)” |
| Group 2: 20/30 to 20/50 | “0.81 (95% CI, 0.73-0.89)” |
| Group 3: 20/60 to 20/100 | “0.57 (95% CI, 0.47-0.67)” |
| Group 4: 20/200 to 20/400 | “0.52 (95% CI, 0.38-0.66)” |
| Group 5: counting fingers to light perception | “0.40 (95% CI, 0.29-0.50)” |

Source: [Brown et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10636413/)

<a id="topic-2.2.1.8.1-3"></a>

###### Time trade-off: lifetime traded for perfect vision

> “Thus, those patients in group 1 were willing to trade 11% of their remaining lifetime in return for perfect vision in each eye, whereas those in group 5 were willing to trade 60% of their remaining lifetime in return for perfect vision in each eye.”
> “Age-related macular degeneration causes a substantial decrease in patient utility values and is highly dependent on the degree of visual loss in the better-seeing eye.”

Source: [Brown et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10636413/)

<a id="topic-2.2.1.8.1-4"></a>

###### Vision-related quality of life and mental health by visual acuity

> “Eight hundred seventy-five patients were included in the study.”
> “When stratified by VA, patients with a habitual VA of 20/200 or worse scored the lowest on mental health subscales scores: median of 43.8 (IQR: 31–62). Patients with a VA of 20/20 scored the highest: 87.5 (IQR: 81–94).”

Source: [Fonteh et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526530/)

<a id="topic-2.2.1.8.1-5"></a>

###### Guideline statement on quality of life

> “Age-related macular degeneration is associated with depression and reduced vision-related quality of life.”
> “Early detection and treatment of AMD to arrest the deterioration in vision may help preserve patients’ quality of life and independence.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.8.1-6"></a>

###### Emotional burden of intravitreal injections

> “In total, 130 patients responded to the survey. The majority of patients reported to receive nine or more injections per year (48.8%), and many patients needed caregiver support for every treatment appointment (37.7%). Patients reported to be anxious one day (25.4%), two days (8.5%), one week (10.8%) or more than one week (3.1%) prior to treatment. The week before the treatment, 33.1% of patients reported to be stressed and 15.4% struggled to sleep. The majority of patients reported the treatment as uncomfortable (54.6%) or as somewhat painful (26.2%).”

Source: [Reitan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10226541/)

<a id="topic-2.2.1.8.1-7"></a>

###### Barriers to treatment reported by patients and caregivers

> “Most patients (65.4%; n=595/910) and caregivers (77.0%; n=685/890) reported a number of obstacles in managing wAMD (Figure 2). For patients, the main barrier was the treatment itself (34.8%; n=317/910)”

Source: [Varano et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4671808/)

<a id="topic-2.2.1.8.1-8"></a>

###### Utility values by visual acuity used in a US cost-utility model

> “Mean vision measurements in the VEGF-I cohorts and control cohorts each year were converted to utility format, ranging from a utility of 0.80 for 20/40 vision in the better-seeing eye to 0.538 associated with 20/630 vision, to calculate the yearly QALY accrual associated with therapy versus none”
> “The time tradeoff utilities were obtained from a visual utility database of 1,400 ophthalmic patient interviews.”

Source: [Brown et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32565050/)

<a id="topic-2.2.1.8.1-9"></a>

###### Clinic time and post-injection recovery time reported by patients

> “More than one-third (36%, 27 of 75) of patients reported that their most recent visit took 90 minutes or more, and 79% (59 of 75) reported spending at least 3 hours recovering following injections.”

Source: [Prenner et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26142721/)

Additional sources: [Butt et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27637920/); [Sharma et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10959467/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Summary: economic burden and resource utilization

In 2024, Medicare Part B spending was $2.37 billion for aflibercept 2 mg (Eylea), $1.92 billion for faricimab (Vabysmo), $0.67 billion for aflibercept 8 mg (Eylea HD), and $0.13 billion for ranibizumab (Lucentis); these totals include all approved indications (for example, diabetic macular edema and retinal vein occlusion), not neovascular AMD alone. In 2020, aflibercept was the second-highest Medicare Part B drug by total spending (more than $3 billion). In a US commercial claims cohort of 6,076 participants with neovascular AMD, annual neovascular AMD-related outpatient visit costs were $8,658 for active choroidal neovascularization compared with $2,406 for inactive disease. In a US survey of 200 participants, mean annual societal ophthalmic costs were $39,910 with visual loss and $6,116 with good vision, rising to $82,984 at 20/800 or worse. Each treatment visit required a mean of 90 minutes in clinic, and patients reported almost 12 hours per visit including travel and recovery. In the IRIS Registry, 11.6% of 156,327 treatment-naive participants were lost to follow-up within 12 months.

Source: [CMS Medicare Part B Spending by Drug (2026)](https://data.cms.gov/sites/default/files/2026-06/6616fc91-eb70-404c-9f27-1448e47a3a73/DSD_PTB_RY26_P06_V10_DYT24_HCPCS-%20260602.csv); [Dickson and James (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10492178/); [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/); [Brown et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26428606/); [Prenner et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26142721/); [Khurana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36858288/)

<a id="topic-2.2.1.8.2-2"></a>

###### Medicare Part B spending on intravitreal anti-VEGF products, 2024 (all indications)

| HCPCS code and product | Total spending, 2024 ($) | Claims, 2024 | Beneficiaries, 2024 |
| --- | --- | --- | --- |
| J0178 aflibercept 1 mg (Eylea) | “2365369089” | “1233027” | “293280” |
| J2777 faricimab-svoa 0.1 mg (Vabysmo) | “1918151107” | “792936” | “172503” |
| J0177 aflibercept hd 1 mg (Eylea Hd) | “665780687.8” | “211930” | “66767” |
| J2778 ranibizumab 0.1 mg (Lucentis) | “128919304.6” | “144995” | “33741” |
| J9035 bevacizumab 10 mg (Avastin) | “161538584.4” | “342609” | “98961” |

Source: [CMS Medicare Part B Spending by Drug (2026)](https://data.cms.gov/sites/default/files/2026-06/6616fc91-eb70-404c-9f27-1448e47a3a73/DSD_PTB_RY26_P06_V10_DYT24_HCPCS-%20260602.csv)

<a id="topic-2.2.1.8.2-3"></a>

###### Medicare Part B spending on AMD therapies, 2020

> “Aflibercept was the second most expensive drug by total spending for the Medicare Part B program in 2020, with more than $3 billion in annual costs, while ranibizumab was the sixth most expensive drug by total spending, costing more than $1 billion; spending on aflibercept and ranibizumab together was more than 10% of the total Medicare Part B drug spending for 2020.”
> “These cost differences have implications for both the Medicare program and beneficiaries, as these patients are liable for 20% of the treatment cost.”

Source: [Dickson and James (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10492178/)

<a id="topic-2.2.1.8.2-4"></a>

###### Medicare Part B spending per beneficiary, 2011 to 2015

> “On average, Medicare spent $9719 and $9934 annually on each beneficiary receiving ranibizumab and aflibercept injections, respectively.”
> “Ranibizumab and aflibercept costs account for 12% of the Medicare Part B budget annually.”

Source: [Patel (2018)](https://pubmed.ncbi.nlm.nih.gov/31047530/)

<a id="topic-2.2.1.8.2-5"></a>

###### Medicare average sales prices for anti-VEGF agents

> “Medicare Part B average sales prices for ranibizumab 0.3 mg, ranibizumab 0.5 mg, and aflibercept 2 mg were $776, $1,292, and $1,806, respectively, as of October 2022.”
> “Consequences of untreated neovascular AMD include a substantial economic burden on patients, their family, and society.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.1.8.2-6"></a>

###### Direct costs and resource use by disease activity: US commercial claims

> “A total of 6,076 patients with nAMD were identified for the prevalent cohort; 60.1%, 17.2%, and 5.9% had active CNV, inactive CNV, and inactive scar disease stage at index, respectively. The nAMD-related outpatient visit costs were roughly 4 and roughly 7 times higher, respectively, for the active CNV group ($8,658 [SD = $11,612]) compared with the inactive CNV ($2,406 [SD = $5,510]) and inactive scar ($1,198 [SD = $3,035]) groups (P < 0.0001).”
> “A total of 3,623 prevalent patients (59.6%) were eligible for the anti-VEGF treatment patterns analysis (mean [SD] duration of therapy = 7.7 [4.5] months; mean [SD] number of injections = 6.0 [3.7]).”

Source: [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)

<a id="topic-2.2.1.8.2-7"></a>

###### Societal costs by visual acuity in the better-seeing eye

> “The mean annual societal cost for the Control Cohort was $6,116 and for the Study Cohort averaged $39,910 (P < 0.001). Study Subcohort 1 costs averaged $20,339, while Subcohort 4 costs averaged $82,984.”
> “Total societal ophthalmic costs associated with neovascular age-related macular degeneration dramatically increase as vision in the better-seeing eye decreases.”

Source: [Brown et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26428606/)

<a id="topic-2.2.1.8.2-8"></a>

###### Treatment burden: time-and-motion study

> “Fifty-six physicians provided data for 221 patients with neovascular AMD. Patients accounted for 20% of the health care staff's time per week, with an average of 23 staff members. An average patient visit for neovascular AMD was 90 minutes (range: 13 minutes to >4 hours). Patients reported an average time per visit of almost 12 hours, including preappointment preparation (16 minutes), travel (66 minutes), waiting time (37 minutes), treatment time (43 minutes), and postappointment recovery (9 hours).”

Source: [Prenner et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26142721/)

<a id="topic-2.2.1.8.2-9"></a>

###### Loss to follow-up during anti-VEGF therapy: IRIS Registry

> “For neovascular AMD, 11.6% of patients (95% CI, 11.4%-11.7%) were LTFU, and 88.4% of patients were followed up within 12 months.”
> “Nearly 1 of 9 patients with neovascular AMD treated with anti-VEGF injections became LTFU, whereas 1 of 7 patients were nonpersistent.”

Source: [Khurana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36858288/)

<a id="topic-2.2.1.8.2-10"></a>

###### Annual per-patient costs in commercially insured neovascular AMD, 2018 US dollars

> “All costs were adjusted to 2018 US dollars using the medical care component of the Consumer Price Index.”
> “We estimated an annual all-cause cost for patients with nAMD of $24,520 per patient, whereas newly diagnosed patients incurred slightly lower costs ($18,943).”
> “The nAMD-related outpatient costs represented 28% of total costs and 44% of total outpatient costs, respectively, and were driven primarily by anti-VEGF injection-related costs”

Source: [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)

<a id="topic-2.2.1.8.2-11"></a>

###### Annual healthcare resource utilization by baseline disease status: US commercial claims

| Visits over 12 months, mean (SD) | All prevalent nAMD (N = 6,076) | Active CNV (N = 3,653) | Inactive CNV (N = 1,046) | Inactive scar (N = 358) |
| --- | --- | --- | --- | --- |
| All-cause outpatient visits | “30.6 (26.4)” | “31.0 (25.5)” | “27.5 (25.3)” | “27.1 (25.9)” |
| nAMD-related outpatient visits | “6.6 (4.8)” | “7.7 (4.6)” | “4.1 (3.5)” | “2.9 (2.9)” |
| Anti-VEGF-related outpatient visits | “3.9 (4.2)” | “5.1 (4.2)” | “1.3 (2.5)” | “0.5 (1.6)” |
| Optical coherence tomography test-related visits | “4.5 (3.5)” | “5.4 (3.6)” | “2.9 (2.6)” | “1.6 (1.9)” |

Source: [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)

<a id="topic-2.2.1.8.2-12"></a>

###### Determinants of neovascular AMD-related outpatient costs

> “Significant drivers of total nAMD-related costs were the initial anti-VEGF agent and anti-VEGF injection frequency”
> “Multivariate GLM results revealed an increasing trend in costs with increasing anti-VEGF injection frequency; there were 73% higher costs for patients with 4-6 injections to 342% higher costs for those with 10 or more injections compared with those with 1-3 injections over 1 year of follow-up”

Source: [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)

<a id="topic-2.2.1.8.2-13"></a>

###### Anti-VEGF injection frequency and treatment disruption by initial agent

> “Mean duration of therapy (SD) and mean (SD) number of injections was lowest for the bevacizumab group (n = 1,876 [51.8%]; 6.0 [4.6] months and 4.8 [3.3] injections, respectively) compared with the ranibizumab (n = 539 [14.9%]; 7.6 [4.4] months and 6.0 [3.6] injections, respectively) and aflibercept groups (n = 1,208 [33.3%]; 7.9 [4.4] months and 6.1 [3.9] injections, respectively).”
> “Nearly half (48.3%) of all patients (n = 1,750) had a treatment disruption.”

Source: [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)

<a id="topic-2.2.1.8.2-14"></a>

###### Staff members and staff time dedicated to neovascular AMD management per retina practice

| Staff type | Average number involved in neovascular AMD care (range) | Average percentage of a 40-hour work week spent in neovascular AMD care (range) | Average hours per week spent on neovascular AMD, all staff members |
| --- | --- | --- | --- |
| Receptionist | “5 (1–18 people)” | “20% (1%–75%)” | “28 hours” |
| Office manager | “2 (0–10 people)” | “13% (0%–75%)” | “10 hours” |
| Billing manager | “2 (0–6 people)” | “22% (0%–80%)” | “18 hours” |
| Technician, including photographer, scribe and lead technician | “8 (1–50 people)” | “34% (3%–90%)” | “112 hours” |
| Physicians other than retina specialists | “2 (0–18 people)” | “15% (0%–65%)” | “12 hours” |
| Other staff, including medical assistants, optometrists and nurse technicians | “4 (1–12 people)” | “25% (5%–70%)” | “40 hours” |

Source: [Prenner et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26142721/)

<a id="topic-2.2.1.8.2-15"></a>

###### Retina specialist reported burden of monitoring and injection frequency

> “When asked about the impact of activities for monitoring and injection administration on staff time, the majority of the surveyed retina specialists (62%, 35 of 57) felt that frequency of patient monitoring placed a significant burden on staff time. A large percentage of retina specialists (58%, 33 of 57) felt that billing and filing for reimbursement was also a significant burden on staff resources.”
> “Forty-nine percent (28 of 57) of retina specialists reported that the frequency of injections was an impactful burden on office space, including waiting rooms and examination rooms.”
> “Two-thirds of physicians (38 of 57) stated they would find it very desirable to reduce office visits.”

Source: [Prenner et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26142721/)

Additional sources: [Franco et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42479493/); [Schmidt et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42426273/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Wet age-related macular degeneration on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Summary: economic impact on families

Caregivers of people receiving anti-VEGF therapy carry a documented time and cost burden. In a UK survey of 250 patient-caregiver pairs, 70.8% of caregivers had attended 10 or more appointments in the previous year, 24.8% required time off work, and caregivers reported loss of income as a consequence. In a US time-and-motion study, caregivers took time away from work (22%) and personal activities (28%) to provide transportation. In a nine-country survey, 56.7% of 910 participants were usually taken to appointments by a caregiver, and a caregiver being unable to take the patient was the most common reason for a missed appointment (25.9%). In a US societal cost survey, direct nonmedical costs, primarily caregiver costs, made up 67.1% of societal ophthalmic costs in participants with visual loss.

Source: [Gohil et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4461306/); [Prenner et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26142721/); [Varano et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4671808/); [Brown et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26428606/)

<a id="topic-2.2.1.8.3-2"></a>

###### Caregiver costs as a share of societal costs

> “Direct nonmedical costs, primarily caregiver, comprised 67.1% of Study Cohort societal ophthalmic costs, versus 21.3% ($1,302/$6,116) of Control Cohort costs (P < 0.001) and 74.1% of 20/800 to no light perception subcohort costs.”

Source: [Brown et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26428606/)

<a id="topic-2.2.1.8.3-3"></a>

###### Caregiver time away from work for transportation to appointments

> “Patients stated that caregivers took time away from work (22%) and personal activities (28%) to provide transportation to appointments.”

Source: [Prenner et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26142721/)

<a id="topic-2.2.1.8.3-4"></a>

###### Caregiver burden during ranibizumab therapy: UK survey

> “This is a cross-sectional questionnaire survey of 250 matched patient caregiver dyads across three large ophthalmic treatment centres in United Kingdom.”
> “The most common eye-related care activity undertaken was accompanying patients for their eye clinic appointments, with 70.8% carers having attended ≥10 appointments over the last year. On an average, the caregivers reported that 70% spent at least half a day and 43.6% spent most of the day assisting their patient with their clinic visit every 4–6 weeks. 24.8% of caregivers required time off work to support patients with their eye treatment, and 10% of them reported that this led to a loss of income.”
> “Ranibizumab therapy for nAMD is associated with significant caregiver burden. Both disease impact and treatment frequency contributed to the overall burden.”

Source: [Gohil et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4461306/)

<a id="topic-2.2.1.8.3-5"></a>

###### Escorts to injection visits and missed appointments: nine-country survey

> “The majority of patients (82.1%; n=747/910) received support from a caregiver.”
> “Most caregivers always attended appointments (60.1%; n=535/890)”
> “For the 15.7% (n=143/910) of patients who missed a clinic appointment, the main obstacles were that the caregiver was unable to take them to the appointment (25.9%; n=37/143), fear about receiving an injection (21.0%; n=30/143), and patient illness (reason not stated) (18.9%; n=27/143).”
> “Most patients (56.7%; n=516/910) were usually taken to the appointment by a caregiver; however, 20.4% (n=186/910) went by public transport, 12.4% (n=113/910) drove themselves, 8.1% (n=74/910) used a taxi, and 2.3% (n=21/910) were taken by an ambulance.”
> “Other barriers included treatment costs (27.8%; n=253/910)”

Source: [Varano et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4671808/)

<a id="topic-2.2.1.8.3-6"></a>

###### Caregiver distress and respite

> “Most caregivers were family caregivers and were found to be compassionate and self-sacrificing. They accepted additional responsibility whilst providing an encouraging environment for their care recipient. As a result, they experience distress and consider their own needs as secondary. Very few seek or receive respite and this added burden can have a negative impact upon the relationship between caregiver and care recipient.”

Source: [Vukicevic et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4791694/)

<a id="topic-2.2.1.8.3-7"></a>

###### Who transports patients to injection visits: US time-and-motion survey

> “The majority of patients (72%, 54 of 75) were driven to their appointment by a caregiver. Their caregiver was a spouse or partner (65%, 35 of 54), an adult child or grandchild (22%, 12 of 54), a friend (7%, 4 of 54), or another person (6%, 3 of 54).”
> “Twenty percent (15 of 75) of patients drove themselves, while 8% (6 of 75) took a car service or public or government transportation.”

Source: [Prenner et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26142721/)

<a id="topic-2.2.1.8.3-8"></a>

###### Out-of-pocket transportation costs and household income of participants

> “Few patients experienced direct out-of-pocket transportation costs. Eighty-nine percent (67 of 75) reported that they did not pay any transportation costs for their latest clinic visit. Among those who had out-of-pocket transportation cost, 12% (8 of 67) paid for parking, 6% (4 of 67) paid tolls, and 3% (2 of 67) paid bus fare.”
> “The average income was $40 000. The majority of patients (62%, 46 of 75) reported an income of less than or equal to $50 000.”

Source: [Prenner et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26142721/)

<a id="topic-2.2.1.8.3-9"></a>

###### Composition of caregiver costs and employment effects of severe vision loss

> “Direct nonmedical, or caregiver, costs included 27% for paid caregivers and 73% for unpaid caregivers,”
> “Inside activities of daily living costs comprised 50% of caregiver costs.”
> “Those with severe difficulty seeing (<20/200), however, earned a median $2,564 per month (98% that of a nondisabled person) but were only 47% as likely to be employed as people without disabilities.”

Source: [Brown et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32565050/)

Additional sources: [Viola et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39208778/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Summary: economic impact of diagnostic testing

Diagnosis and retreatment decisions rely on retinal imaging, principally OCT (CPT 92134), with fluorescein angiography when indicated. In a US Medicare analysis covering 2008 to 2015, reimbursement for OCT imaging used to guide anti-VEGF therapy for neovascular AMD totaled an estimated $0.8 billion, while OCT-guided personalized dosing was estimated to have saved Medicare $10.3 billion in anti-VEGF drug and injection costs, for a net government saving of $9.0 billion. The estimated annual beneficiary copayment for OCT imaging was $6, compared with $242 for aflibercept on a personalized injection schedule. No current Medicare fee schedule amount for OCT or fluorescein angiography was retrieved from a primary CMS source.

Source: [Windsor et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5732022/)

<a id="topic-2.2.1.8.4-2"></a>

###### Medicare spending on OCT imaging and savings from OCT-guided therapy

> “Using the meta-analysis and survey data, we calculated the cost of using OCT imaging to guide anti-VEGF treatment decisions from 2008– 2015 was $0.8 billion.”
> “Compared to the fixed-regimen spending totals, OCT-guided personalized-treatment regimens enabled Medicare to save $10.3 billion dollars on anti-VEGF therapy costs for nvAMD from 2008 – 2015.”
> “From 2008 – 2015, the United States government and nvAMD patients have accrued an estimated savings of $9.0 billion and $2.2 billion, respectively, from the use of OCT to guide personalized anti-VEGF treatment.”

Source: [Windsor et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5732022/)

<a id="topic-2.2.1.8.4-3"></a>

###### Beneficiary copayment for OCT imaging

| Cost component | Ranibizumab | Bevacizumab | Aflibercept |
| --- | --- | --- | --- |
| Drug copay cost, personalized-injection schedule | “$288” | “$9” | “$242” |
| OCT imaging copay cost, personalized-injection schedule | “$6” | “$6” | “$6” |
| Injection copay cost, personalized-injection schedule | “$20” | “$20” | “$20” |

Source: [Windsor et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5732022/)

<a id="topic-2.2.1.8.4-4"></a>

###### Imaging billing codes used in Medicare claims analysis

> “Main outcome measures were spending by Medicare as tracked by Current Procedural Terminology codes on intravitreal injections (67028), retinal OCT imaging (92134) and anti-VEGF treatment-specific J-codes (J0178, J2778, J9035, J3490 and J3590).”

Source: [Windsor et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5732022/)

<a id="topic-2.2.1.8.4-5"></a>

###### Optical coherence tomography visits over 12 months by baseline disease status

| Optical coherence tomography test-related visits over 12 months | All prevalent nAMD (N = 6,076) | Active CNV (N = 3,653) | Inactive CNV (N = 1,046) | Inactive scar (N = 358) |
| --- | --- | --- | --- | --- |
| Patients with at least 1 visit, n (%) | “5,350 (88.1)” | “3,384 (92.6)” | “893 (85.4)” | “253 (70.7)” |
| Number of unique visits, mean (SD) | “4.5 (3.5)” | “5.4 (3.6)” | “2.9 (2.6)” | “1.6 (1.9)” |

Source: [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Anti-VEGF Intravitreal Injections

<a id="topic-2.2.2.1.1-1"></a>

###### Anti-VEGF therapy as first-line treatment for neovascular AMD

> “Anti-VEGF therapies have become first-line therapy for treating and stabilizing most cases of neovascular AMD, and a Cochrane systematic review demonstrates the effectiveness of these agents to maintain VA.”
> “Adverse events for all anti-VEGF agents include rare risks of arterial thromboembolic events, endophthalmitis, and elevated intraocular pressure.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.1-2"></a>

###### NICE recommendation for anti-VEGF treatment of late AMD (wet active)

> “Offer intravitreal anti-vascular endothelial growth factor (VEGF) treatment for late AMD (wet active) for eyes with visual acuity within the range specified in recommendation 1.5.6.”
> “Be aware that no clinically significant differences in effectiveness and safety between the different anti-VEGF treatments have been seen in the trials considered by the guideline committee.”

Source: [NICE (2018)](https://www.nice.org.uk/guidance/ng82/chapter/Recommendations)

<a id="topic-2.2.2.1.1-3"></a>

###### Aflibercept 2 mg and 8 mg

> “the 2-mg dose has been documented to be of similar efficacy to ranibizumab in the head-to-head phase-3 VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) trials.”
> “The 48-week results showed that after three monthly loading doses, aflibercept 8 mg showed achieved noninferior VA gains at 12-week and 16-week treatment intervals compared with aflibercept 2 mg at 8-week treatment intervals.”
> “The safety profile of aflibercept 8 mg was found to be similar to that of aflibercept 2 mg.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.1-4"></a>

###### Ranibizumab 0.5 mg

> “Ranibizumab 0.5-mg was approved by the FDA for the treatment of all subtypes of neovascular AMD, based on results from three double-masked, randomized controlled trials.”
> “Ranibizumab was well tolerated in randomized controlled trials with a safety profile similar to that of other anti-VEGF agents.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.1-5"></a>

###### Bevacizumab (off-label intravitreal use)

> “Because preliminary reports appeared favorable, ophthalmologists began using intravitreal bevacizumab off-label to treat MNV.”
> “Presently, there does not appear to be a significant difference in efficacy between ranibizumab and bevacizumab.”
> “A real-world analysis of 13,859 patients found that all three agents improved VA similarly over 1 year.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.1-6"></a>

###### Brolucizumab

> “Results from the HAWK and HARRIER phase 3 clinical trials showed that brolucizumab achieved its primary endpoint of noninferiority of BCVA change compared with aflibercept at week 48.”
> “After FDA approval, several cases of occlusive retinal vasculitis occurred after intravitreal brolucizumab injection.”
> “Brolucizumab is approved for use every 8 to 12 weeks after the loading period, and more frequent administration should be avoided.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.1-7"></a>

###### Ranibizumab and aflibercept biosimilars

> “In 2024, the FDA approved five biosimilars to aflibercept 2 mg as of November 2024”
> “All are injected intravitreally as a 2-mg solution, and the adverse events appear comparable to aflibercept.”
> “When used, the choice of biologic product (reference, biosimilar, or interchangeable) should be that of the treating ophthalmologist and the patient because patients may respond more favorably to one biologic over another.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.1-8"></a>

###### Aflibercept 8 mg: participants maintaining 12-week and 16-week intervals through week 48 in PULSAR

> “A total of 251 (79%) of 316 patients in the aflibercept 8q12 group and 239 (77%) of 312 patients in the aflibercept 8q16 group maintained their assigned dosing regimen up to week 48. Overall, 523 (83%) of 628 patients who received aflibercept 8 mg maintained at least 12-week dosing intervals up to week 48.”
> “Least squares mean change from baseline in BCVA letter score at week 48 was +6·1 (95% CI 4·6–7·6) letters in the aflibercept 8q12 group, +5·9 (4·5–7·3) letters in the 8q16 group, and +7·0 (5·6–8·5) letters in the aflibercept 2q8 group”

Source: [Lanzetta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38461841/)

<a id="topic-2.2.2.1.1-9"></a>

###### Aflibercept 8 mg and 2 mg: serious ocular events, intraocular inflammation, and thromboembolic events in PULSAR

> “Serious ocular TEAEs in the study eye occurred in 13 (1·3%) of 1009 patients”
> “no cases of endophthalmitis or retinal vasculitis were reported. All cases of intraocular inflammation were mild or moderate in severity.”
> “Eight cases of arteriothrombotic events, assessed and categorised by an Anti-Platelet Trialists’ Collaboration adjudication committee, were reported, with no clinically relevant differences observed across groups”

Source: [Lanzetta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38461841/)

<a id="topic-2.2.2.1.1-10"></a>

###### Aflibercept: intraocular inflammation and vision loss with denominators in HAWK and HARRIER, and postmarketing occlusive event rate

> “The SRC reviewed data from cases of investigator-reported IOI (60/1088 brolucizumab-treated eyes; 8/729 aflibercept-treated eyes).”
> “Incidence of IOI in aflibercept-treated eyes was 1.1%, with at least moderate visual acuity loss in 0.14%.”
> “The overall rates of moderate or severe visual acuity loss, including visual acuity loss associated with definite/probable IOI, retinal vasculitis, and/or retinal occlusion, were 7.4% (81/1088) and 7.7% (56/729) in brolucizumab- and aflibercept-treated eyes, respectively.”
> “A recent review of data from the postmarketing aflibercept Global Safety Database indicated that retinal arterial occlusion, vasculitis, or severe vision loss occurred at a rate of 0.9 per 10 000 aflibercept injections.”

Source: [Monés et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33207259/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Bispecific Anti-VEGF and Angiopoietin-2 Antibodies

<a id="topic-2.2.2.1.2-1"></a>

###### Faricimab: mechanism and approval

> “Faricimab-svoa, a humanized bispecific monoclonal antibody for intravitreal use that acts through dual inhibition of both angiopoietin-2 and VEGF-A, was approved by the FDA for the treatment of patients with neovascular AMD.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.2-2"></a>

###### Faricimab: TENAYA and LUCERNE dosing intervals and injection counts

> “Approximately 80% of eyes could be dosed every 12 weeks or more, and 45% could be dosed every 16 weeks in year 1 and increased to 63% in year 2.”
> “Through year 2, the median number of injections in the faricimab group was 10, compared with 15 for aflibercept.”
> “There were no new safety signals, and adverse events were comparable to aflibercept 2 mg.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.2-3"></a>

###### Faricimab: intraocular inflammation and retinal vasculitis reports

> “Recently, case reports of intraocular inflammation (excluding endophthalmitis) with faricimab were as high as 2% and retinal vasculitis with or without occlusion were 0.17 per 10,000 injections (vasculitis) and 0.06 per 10,000 for occlusive vasculitis.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.2-4"></a>

###### Faricimab: dosing interval distribution at week 48 in TENAYA and LUCERNE with participant counts

> “At week 48, approximately 80% of faricimab-treated patients in both TENAYA and LUCERNE were on 12-week or 16-week dosing intervals, with 107 (34·0%) patients in TENAYA and 104 (32·9%) patients in LUCERNE on extended dosing regimens of every 12 weeks, and 144 (45·7%) patients in TENAYA and 142 (44·9%) patients in LUCERNE on 16-week dosing”
> “More than 95% of patients in the faricimab group in both studies avoided losing 15 letters or more of vision from baseline at primary endpoint visits”

Source: [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/)

<a id="topic-2.2.2.1.2-5"></a>

###### Faricimab and aflibercept: intraocular inflammation and endophthalmitis in TENAYA and LUCERNE

> “In TENAYA and LUCERNE, at week 48, rates of intraocular inflammation were low and on average reported in 2·0% of patients receiving faricimab and 1·2% of patients receiving aflibercept”
> “Two intraocular inflammation events (one uveitis in TENAYA, one vitritis in LUCERNE) in the faricimab group and one uveitis event (LUCERNE) in the aflibercept group led to a decrease of 30 or more letters in visual acuity score lasting more than 1 h”
> “There was one report of endophthalmitis in the aflibercept group of LUCERNE, which was culture negative.”

Source: [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Port Delivery System with Ranibizumab

<a id="topic-2.2.2.1.3-1"></a>

###### Surgically implanted refillable ranibizumab reservoir

> “The FDA approved ranibizumab 100 mg/ml for use with an ocular implant that continuously releases the medication over 6 months.”
> “The implant is surgically inserted into the eye in the operating room and can be refilled every 6 months with an office procedure.”
> “Approximately 98% of patients could receive continuous treatment for 6 months before requiring a refill or supplemental ranibizumab.”
> “In 2022, the implant was voluntarily recalled due to concerns about septum dislodgment.”
> “The implant was re-introduced to the market in 2024.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.3-2"></a>

###### Endophthalmitis across Ladder, Archway, and Portal

> “The United States Prescribing Information has a Boxed Warning for endophthalmitis”
> “Twelve endophthalmitis events were reported in 11 patients (11/555 [2.0%]) through March 12, 2021.”
> “Seven cases (7/11 [63.6%]) had preceding/concurrent conjunctival complications.”

Source: [Eichenbaum et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39154860/)

<a id="topic-2.2.2.1.3-3"></a>

###### Archway: ocular adverse events of special interest with denominators through week 40

> “Ocular adverse events of special interest were reported in 47 patients (19.0%) and 10 patients (6.0%) in the PDS Q24W and monthly ranibizumab arms, respectively.”
> “endophthalmitis occurred in 4 patients (1.6%) in the PDS Q24W arm; all events were serious and occurred outside of the postoperative period at days 57, 59, 161, and 282.”
> “Iritis occurred in 50 patients (20.2%) in the PDS Q24W arm, with 48 patients experiencing events in the postoperative period, consistent with expected postoperative inflammation.”
> “In the PDS Q24W arm, 18 patients (7.3%) required 22 additional surgical procedures related to ocular adverse events of special interest, including cataract extraction, conjunctival repair, and vitrectomy.”

Source: [Holekamp et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34597713/)

<a id="topic-2.2.2.1.3-4"></a>

###### Archway: supplemental ranibizumab before the first refill-exchange

> “A total of 246 PDS-treated patients were assessed for supplemental ranibizumab treatment at week 16, week 24, or both, excluding 2 patients who discontinued study treatment before week 16.”
> “In total, 4 PDS-treated patients (1.6%) who were assessed for supplemental treatment received supplemental treatment before the first refill-exchange procedure.”

Source: [Holekamp et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34597713/)

<a id="topic-2.2.2.1.3-5"></a>

###### Port delivery system endophthalmitis: basis of the boxed warning, severity, and timing of onset

> “This warning was issued due to the observation that PDS-treated patients experienced endophthalmitis at a 3-fold higher rate (1.7%) compared with patients receiving monthly intravitreal injections (0.5%) during the controlled phase of the PDS nAMD studies of Ladder and Archway.”
> “all patients experienced moderate (4/11 [36.4%]) or severe (7/11 [63.6%]) endophthalmitis when events were analyzed by greatest intensity.”
> “There were 2 cases (2/555 [0.4%]) of postoperative endophthalmitis consistent with acute postoperative endophthalmitis. All other cases had a late onset and occurred >37 days after the PDS implant insertion procedure and were consistent with delayed onset endophthalmitis.”

Source: [Eichenbaum et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39154860/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Verteporfin Photodynamic Therapy

<a id="topic-2.2.2.1.4-1"></a>

###### Current role of photodynamic therapy in the United States

> “Although current practice patterns support anti-VEGF monotherapy for exudative neovascular AMD, verteporfin PDT remains approved for the treatment of subfoveal lesions and can be used in certain situations.”
> “However, the EVEREST study demonstrated that fewer anti-VEGF injections were needed in combination therapy compared with anti-VEGF monotherapy in eyes with the PCV variant of neovascular AMD.”
> “A severe decrease in central vision occurred within 1 week following treatment in 1% to 4% of patients, which may be permanent”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.4-2"></a>

###### NICE recommendations on photodynamic therapy

> “Do not offer photodynamic therapy alone for late AMD (wet active).”
> “Do not offer photodynamic therapy as an adjunct to anti-VEGF as first-line treatment for late AMD (wet active).”

Source: [NICE (2018)](https://www.nice.org.uk/guidance/ng82/chapter/Recommendations)

<a id="topic-2.2.2.1.4-3"></a>

###### EURETINA recommendation on laser photocoagulation and photodynamic therapy

> “While largely superseded by intravitreal pharmaceutical VEGF inhibition, these two older forms of CNV treatment remain a rational therapeutic option for selected patients in whom VEGF inhibition is not advisable.”

Source: [Schmidt-Erfurth et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4145443/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 AREDS2 Antioxidant Vitamin and Mineral Supplementation

<a id="topic-2.2.2.1.5-1"></a>

###### Fellow-eye risk reduction in unilateral neovascular AMD

> “Treatment with antioxidants and minerals as described previously in the original AREDS and AREDS2 trials should be considered for patients who have progressed to intermediate or advanced AMD in at least one eye.”
> “For patients with unilateral disease, the fellow eye without MNV remains at high risk of developing advanced AMD.”
> “The risk can be lowered by as much as 36% over a 10-year period by taking the AREDS/AREDS2 supplements.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Limitations of Current Therapies

<a id="topic-2.2.2.1.6-1"></a>

###### Summary

Current treatment of neovascular AMD relies on repeated intravitreal injections of anti-VEGF agents given monthly, every 8 weeks, or at extended intervals of up to 16 weeks under treat-and-extend or personalized-interval regimens, with continuous office monitoring. Real-world patients receive fewer injections than trial participants and have smaller visual gains: in 49,485 treatment-naive United States eyes, the mean gain at 1 year was 0.95 letter after a mean of 7.3 injections; in the eight-country AURA study (2,227 patients), mean gains were +2.4 letters at year 1 and +0.6 letters at year 2 with 5.0 and 2.2 injections; and in LUMINOUS (3,379 treatment-naive patients with 1-year data), the mean gain was 3.1 letters with 5.0 injections. In one United States retina practice, 2,003 of 9,007 patients (22.2%) were lost to follow-up for 12 months or longer after an injection. In CATT, vision gains from the first 2 years were not maintained at 5 years. Agent-specific safety limitations include intraocular inflammation with retinal vasculitis or occlusion after brolucizumab (definite or probable intraocular inflammation in 4.6% of brolucizumab-treated eyes in HAWK and HARRIER) and endophthalmitis in 11 of 555 participants (2.0%) who received the port delivery system with ranibizumab, which carries a boxed warning and was voluntarily recalled in 2022 before reintroduction in 2024. Payer prior authorization requests for anti-VEGF agents were approved in 96.2% of cases but delayed care by more than 24 hours in 59.6% of approvals.

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp); [Ciulla et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31324588/); [Holz et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4316940/); [Holz et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447127/); [Obeid et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583857/); [Monés et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33207259/); [Eichenbaum et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39154860/); [Dang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11211988/)

<a id="topic-2.2.2.1.6-2"></a>

###### Real-world undertreatment and visual outcomes: United States retina database

> “At 1 year, after a mean of 7.3 anti-VEGF injections, there was a mean gain of 1 letter (0.95 letter; 95% confidence interval [CI] for change in VA, +0.77 to +1.13 letter; P < 0.001).”
> “Real-world nAMD patients receive fewer anti-VEGF injections and experience worse visual outcomes compared with patients receiving fixed, frequent therapy in randomized controlled trials.”
> “Older patients and those with poor baseline VA may be particularly prone to undertreatment.”

Source: [Ciulla et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31324588/)

<a id="topic-2.2.2.1.6-3"></a>

###### Real-world visual outcomes: AURA multi-country study

> “Mean change in visual acuity score from baseline to years 1 and 2 was +2.4 and +0.6 letters, respectively.”
> “Patients received a mean of 5.0 and 2.2 injections in the first and second year, respectively.”
> “In clinical practice, fewer injections are administered than in clinical trials. Anti-VEGF treatment resulted in an initial improvement in visual acuity; however, this was not maintained over time.”

Source: [Holz et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4316940/)

<a id="topic-2.2.2.1.6-4"></a>

###### Real-world visual outcomes: LUMINOUS treatment-naive patients

> “The mean (SD) visual acuity (VA; letters) gain at 1 year was 3.1 (16.51) (n = 3,379; BLVA, 51.9 letters [Snellen: 20/92]) with a mean (SD) of 5.0 (2.7) injections and 8.8 (3.3) monitoring visits.”

Source: [Holz et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447127/)

<a id="topic-2.2.2.1.6-5"></a>

###### Nonadherence and loss to follow-up

> “Real-world treatment tends to fall short of clinical trial guidelines and protocols, and it results in worse outcomes.”
> “Loss to follow-up is not uncommon in patients with neovascular AMD.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.6-6"></a>

###### Loss to follow-up in a United States retina practice

> “Among the 9007 patients (mean [SD] age, 81.2 [8.8] years; 5917 [65.7%] female; 7905 [87.8%] white), 2003 (22.2%) were LTFU.”

Source: [Obeid et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583857/)

<a id="topic-2.2.2.1.6-7"></a>

###### Long-term vision loss despite anti-VEGF treatment

> “The CATT 5-year follow-up study demonstrated that vision gains during the first 2 years were not maintained at 5 years.”
> “The PRN regimens using ranibizumab appear to have efficacy and safety comparable to fixed monthly regimens over 1 year of treatment, but they do not maintain the initial visual gains with longer follow-up.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.6-8"></a>

###### Injection frequency and treatment burden: sponsor description

> “These treatments are injected in a physician’s office either monthly, bi-monthly or in some patients every three to four months, which can cause inconvenience and often leads to reduced compliance and poor outcomes.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.2.2.1.6-9"></a>

###### Brolucizumab: intraocular inflammation, retinal vasculitis, and occlusion

> “On the basis of these cases, incidence of definite/probable IOI was 4.6% (IOI + vasculitis, 3.3%; IOI + vasculitis + occlusion, 2.1%).”
> “There were 8 cases (incidence 0.74%) of at least moderate visual acuity loss (≥15 ETDRS letters) in eyes with IOI (7 in eyes with IOI + vasculitis + occlusion).”

Source: [Monés et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33207259/)

<a id="topic-2.2.2.1.6-10"></a>

###### Brolucizumab every 4 weeks in recalcitrant disease

> “However, the incidence of intraocular inflammation, including retinal vasculitis and retinal vascular occlusion, was 11.5% for brolucizumab and 6.1% for aflibercept.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.6-11"></a>

###### Port delivery system with ranibizumab: endophthalmitis and device complications

> “Importantly, after using the implant, there was a 2% risk of endophthalmitis in clinical trials (a rate three times higher than monthly intravitreal injections of ranibizumab).”
> “Other risks included vitreous hemorrhage, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, conjunctival erosion, conjunctival retraction, and conjunctival blebs.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.1.6-12"></a>

###### Prior authorization delays for anti-VEGF agents

> “Of the 2140 approvals, 59.6% (1277) resulted in a delay in care greater than 24 hours, and 40% (863) were given on the date of service.”
> “The median staff time spent to obtain a single PA was 100 (range, 0-200) minutes.”

Source: [Dang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11211988/)

<a id="topic-2.2.2.1.6-13"></a>

###### Monitoring visits during extended-interval dosing in the faricimab phase 3 trials

> “Finally, the assessment of the potential for faricimab to reduce treatment burden and improve quality of life might also be limited by the fact that at the time of the primary analysis, all patients returned for monthly visits to maintain masking.”

Source: [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/)

<a id="topic-2.2.2.1.6-14"></a>

###### Brolucizumab: postmarketing event rates per 10 000 injections and timing of inflammation onset

> “On August 28, 2020, postmarketing data indicated that Novartis had received reports of evidence of associated retinal vasculitis and retinal vascular occlusion at a rate of 4.71 per 10 000 brolucizumab injections, while individual events of retinal vasculitis and retinal vascular occlusion were reported at rates of 3.61 and 2.35 per 10 000 injections, respectively.”
> “Approximately three quarters of cases of each event occurred within the initial 6 months after the first injection.”
> “Notably, patients whose first IOI-related event occurred more than 12 months after the first injection had no reported vision loss at the end of the study.”

Source: [Monés et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33207259/)

<a id="topic-2.2.2.1.6-15"></a>

###### Visual acuity change by anti-VEGF injection count over 1 year

> “At the lower range, those patient eyes that received 4 anti-VEGF injections or fewer in the first year of treatment generally lost vision, approximately 2 to 3 letters at 1 year.”
> “In the mid range, a linear relationship was found between mean letters gained and mean number of anti-VEGF injections, up to 10 injections over 1 year, after which the relationship plateaued at approximately 3 to 4 letters gained.”
> “Patient eyes that received 4 anti-VEGF injections or fewer over 1 year generally showed worse mean baseline VA than those patient eyes that received a greater number of injections over 1 year.”
> “Those who received 1 anti-VEGF injection had a mean baseline age of 81.1 years, whereas those who received 13 injections over 1 year had a mean baseline age of 78.4 years”

Source: [Ciulla et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31324588/)

<a id="topic-2.2.2.1.6-16"></a>

###### Variable-frequency regimens and the gap from registration-trial outcomes

> “Registration trials for ranibizumab (monthly) and aflibercept (every 2 months after 3 monthly loading doses) and the monthly ranibizumab and bevacizumab arms of CATT show an average 1-year improvement of 8.5 letters across these studies”
> “The 2015 American Society of Retina Specialists Preferences and Trends Survey of more than 2700 retina specialists in 60 countries revealed that more than 90% of retina specialists, both in the United States and internationally, use OCT-guided variable frequency anti-VEGF treatment protocols for nAMD.”
> “Multiple prospective RCTs have demonstrated that variable frequency anti-VEGF therapy for nAMD results in a less favorable visual outcome compared with fixed, frequent anti-VEGF suppression.”
> “Consequently, attempts to limit treatment burden through the adoption of variable frequency anti-VEGF treatment regimens must be approached cautiously.”

Source: [Ciulla et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31324588/)

<a id="topic-2.2.2.1.6-17"></a>

###### Loss to follow-up and nonpersistence: national registry rates and risk factors

> “This big data retrospective cohort study from the IRIS Registry of 185 138 eyes of 156 327 patients who were documented with treatment-naive neovascular AMD and subsequently were treated with anti-VEGF therapy in the United States disclosed an LTFU rate of 11.6%.”
> “Risk factors for being LTFU included increasing age, male sex, Black or African American race or ethnicity, diabetes, unilateral involvement, and Medicaid health insurance. The rate of nonpersistence in this same cohort was 14.3%.”
> “Health insurance is also a risk factor because patients with Medicaid insurance were more likely to be LTFU and nonpersistent, whereas patients with Medicare insurance were less likely to be LTFU and nonpersistent than patients with private insurance.”
> “Among patients who were LTFU, the average time from the first intravitreal injection to the last visit was 2.4 years and was 4.4 years for patients not LTFU.”

Source: [Khurana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36858288/)

<a id="topic-2.2.2.1.6-18"></a>

###### Visual acuity at last visit by follow-up status

> “Compared with patients without nonpersistence during the same follow-up period, a lower percentage of patients with nonpersistence showed VA of 20/40 or better (35% vs. 43%; P < 0.001) at the last visit”
> “Compared with patients without nonpersistence during the same follow-up period, a higher percentage of patients with nonpersistence lost > 5 ETDRS letters (40% vs. 36%; P < 0.001; Table 5) in the treated eye.”
> “Twelve percent of patients who were LTFU did later undergo follow-up (defined as after the first year and within 4 years of the last anti-VEGF intravitreal injection).”

Source: [Khurana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36858288/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

Vorolanib intravitreal insert is investigational and has not been approved by the FDA. LUGANO (in the full dataset) and LUCIA did not meet their primary best-corrected visual acuity noninferiority endpoints, and on October 19, 2026, EyePoint announced that it would conclude both phase 3 wet AMD trials early and prioritize development in diabetic macular edema; no approved population or label for wet AMD is defined. EyePoint had anticipated a New Drug Application in the first half of 2027, contingent on LUCIA results; on November 12, 2026, it stated that it will conclude the wet AMD program before completion of the full second year of both trials and will complete additional analyses to assess next steps in wet AMD, and it has announced no New Drug Application for wet AMD. In the phase 3 trials, the insert (2.7 mg, delivered as 2 inserts in a single injection) was given every 6 months starting at month 2, after aflibercept loading doses, with supplemental aflibercept allowed by prespecified disease-activity criteria. The trials enrolled both treatment-naive participants (75.4% of the LUGANO insert arm) and previously treated participants, who needed at least 2 anti-VEGF injections in the prior 6 months. The phase 2 DAVIO 2 trial enrolled only previously treated participants. In these designs, the use studied was maintenance therapy after anti-VEGF induction, with rescue anti-VEGF injections as needed, in treatment-naive or previously treated patients. The sponsor expects physicians to incorporate the product into existing treatment approaches. Administration is an office-based intravitreal injection, the same care setting as current anti-VEGF therapy. An independent 2025 review stated that larger controlled trials are needed to define the clinical role of sustained-release tyrosine kinase inhibitors.

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm); [EyePoint LUCIA topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm); [EyePoint strategic prioritization announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-ex99_1.htm); [EyePoint third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526456889/eypt-ex99_1.htm); [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm); [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm); [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064); [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)

<a id="topic-2.2.2.2-2"></a>

###### Investigational status, NDA plan contingent on LUCIA, and early conclusion of the wet AMD trials

> “EyePoint plans to prioritize the development of DURAVYU for the potential treatment of DME, which is expected to read out pivotal Phase 3 topline data in the fourth quarter of 2027.”

Source: [EyePoint strategic prioritization announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-ex99_1.htm)

> “We look forward to a potential New Drug Application (NDA) filing with FDA in the first half of 2027, pending LUCIA results in the fourth quarter of 2026.”
> “DURAVYU is an investigational product; it has not been approved by the FDA.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-2.2.2.2-3"></a>

###### Phase 3 population: treatment-naive and previously treated patients

> “Previously treated or treatment naïve patients with a documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit.”
> “For previously-treated subjects, must have been treated with at least 2 anti-VEGF IVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab, or faricimab) in the previous 6 months for wAMD per standard of care in the study eye prior to the Screening Visit.”

Source: [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)

<a id="topic-2.2.2.2-4"></a>

###### LUGANO and LUCIA enrollment mix

> “In LUGANO and in the second trial, LUCIA, we enrolled 75% treatment-naïve patients and 25% treatment-experienced patients.”

Source: [Duker (2026)](https://retinalphysician.com/issues/2026/july-august/interpreting-the-lugano-trial/)

<a id="topic-2.2.2.2-5"></a>

###### Dosing after anti-VEGF loading

> “Patients in the DURAVYU treatment arm will receive an intravitreal injection of DURAVYU every six months, starting at month two of the trial with a total of four injections over the two-year trial.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.2.2.2-6"></a>

###### Dosing after anti-VEGF loading: LUGANO presentation

> “DURAVYU dosing consists of 2 inserts delivered in a single injection.”
> “After loading doses, 88% of DURAVYU eyes received 2 DURAVYU treatments and 2 or fewer supplemental injections up to Week 56.”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.2.2.2-7"></a>

###### Sponsor-anticipated use

> “our expectations that if approved, physicians would incorporate DURAVYU into existing treatment approaches for a broad range of wet AMD patients”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.2.2.2-8"></a>

###### Sponsor-proposed role alongside current therapies

> “We believe that DURAVYU, if approved as a potential six-month sustained delivery therapy, has the potential to offer wet AMD patients a safe and effective treatment option with a new and complementary multi-MOA to current therapies.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.2.2.2-9"></a>

###### Care setting: office-based intravitreal injection

> “DURAVYU is delivered via a standard intravitreal injection in the physician's office, similar to current practice with FDA approved anti-VEGF treatments.”
> “In clinical practice, keeping patients adequately treated over time is a big challenge, and a sustained delivery option with this kind of profile would be a welcome addition to the armamentarium.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-2.2.2.2-10"></a>

###### Independent review of sustained-release tyrosine kinase inhibitors

> “Sustained delivery of VEGF receptor TKIs represents a promising therapeutic paradigm for retinal and choroidal vascular diseases, potentially reducing treatment burden while maintaining efficacy.”
> “Continued evaluation through larger, controlled clinical trials is essential to validate these early findings and define the role of these agents in clinical practice.”

Source: [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)

<a id="topic-2.2.2.2-11"></a>

###### Independent review: rationale for local rather than systemic delivery of tyrosine kinase inhibitors

> “These systemic profiles inform the safety considerations of repurposing these agents for intraocular or systemic delivery in retinal and choroidal vascular diseases, where minimizing systemic exposure is paramount.”
> “Adverse events such as gastrointestinal symptoms and elevated liver enzymes mirror those commonly reported with systemic TKI use in oncology.”
> “This overlap underscores the importance of optimizing delivery routes to minimize systemic exposure while preserving ocular efficacy.”

Source: [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Summary

Formal subgroup results from LUGANO have not been published; EyePoint stated that subgroup analyses would be presented at retina meetings beginning with the Retina Society meeting of September 23 to 26, 2026. In the topline data, 9 of 211 participants (4%) in the vorolanib insert arm lost 15 or more letters from causes the sponsor attributed to conditions other than wet AMD: geographic atrophy (6), glaucoma (2), and retinal detachment (1). No aflibercept participants lost vision from such causes. Baseline history of glaucoma in the study eye was 11.4% in the insert arm and 5.9% in the aflibercept arm. Geographic atrophy lesions were closer to the fovea at baseline in the insert arm (825 versus 1,009 microns). Excluding these 9 participants was an ad hoc analysis. The prespecified supplement-free subgroup (113 participants, 54%) met noninferiority (nominal p = 0.0035). The EyePoint chief executive officer stated that visual acuity results were similar in treatment-naive and treatment-experienced participants, but no numerical subgroup results have been released. In DAVIO 2, which enrolled only previously treated participants, EyePoint reported that visual and anatomic outcomes were not meaningfully influenced by baseline visual acuity, duration of wet AMD, or prior treatment burden. These subgroup findings are sponsor-reported, partly post hoc, and not peer reviewed.

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm); [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm); [Duker (2026)](https://retinalphysician.com/issues/2026/july-august/interpreting-the-lugano-trial/); [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.2.2.3-2"></a>

###### LUGANO: participants with vision loss unrelated to wet AMD

> “DURAVYU was non-inferior to on-label aflibercept (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD.”
> “In contrast, no patients experienced vision loss (≥ 15 letters) unrelated to wet AMD in the aflibercept control arm.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-2.2.2.3-3"></a>

###### LUGANO: causes of vision loss and baseline geographic atrophy location

> “Cause of Visual Loss in the 9 Patients: Geographic atrophy (n=6) Glaucoma (n=2) Retinal detachment (n=1)”
> “Excluding the cohort, DURAVYU arm gained +3.5 letters”
> “In DURAVYU eyes, GA started meaningfully closer to fovea at baseline compared to control, therefore at higher risk of losing vision”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.2.2.3-4"></a>

###### LUGANO: supplement-free subgroup

> “Pre-specified analysis of change in BCVA from baseline to average Week 52/56 in supplement-free patients showed that DURAVYU was non-inferior (nominal p-value=0.0035) versus on-label aflibercept”
> “The 54% of DURAVYU eyes that were supplement free up to week 56 showed only a 3-micron difference in CST compared to the on-label aflibercept control”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-2.2.2.3-5"></a>

###### LUGANO: treatment-naive versus previously treated participants

> “The results from a visual acuity perspective were similar in both arms. But once again, if you take away those 9 outlier patients, then the results would show noninferiority among all of the dataset.”

Source: [Duker (2026)](https://retinalphysician.com/issues/2026/july-august/interpreting-the-lugano-trial/)

<a id="topic-2.2.2.3-6"></a>

###### LUGANO: planned subgroup presentations

> “EyePoint plans to present additional details on the LUGANO dataset, including subgroup-analyses, at major retina conferences in the coming months, beginning at the Retina Society 59 th Annual Scientific Meeting from September 23-26, 2026.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-2.2.2.3-7"></a>

###### DAVIO 2: consistency across baseline characteristics in previously treated participants

> “Visual and anatomical outcomes were not meaningfully influenced by differences in patient baseline BCVA, duration of wet AMD diagnosis, or historical treatment burden.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.2.2.3-8"></a>

###### Anti-VEGF comparator context: visual gains by baseline visual acuity

> “Stratified by BLVA <23 (n = 382), 23 to <39 (n = 559), 39 to <60 (n = 929), 60 to <74 (n = 994), and ≥74 (n = 515), visual acuity change was 12.6 (20.63), 6.7 (17.88), 3.6 (16.41), 0.3 (13.83), and −3.0 (11.82) letters, respectively.”

Source: [Holz et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447127/)

<a id="topic-2.2.2.3-9"></a>

###### Visual acuity loss by choroidal neovascularization lesion subtype: untreated eyes

> “Based on these studies, at 12 months 33.2% (95% CI, 19.3%-48.7%) of patients with occult choroidal neovascularization had lost between 3 and 6 lines of VA, compared with 43.7% (95% CI, 28.0%- 60.1%) of patients with classic choroidal neovascularization. This difference was not significant, as reflected by the overlapping CIs.”
> “In the 41 treatment arms reporting the location of choroidal neovascularization relative to the fovea, most patients had subfoveal disease (81.4%).”
> “We were unable to confirm or refute the commonly held clinical perception that the natural history of visual function is influenced by angiographic choroidal neovascularization subtype.”

Source: [Wong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17675159/)

<a id="topic-2.2.2.3-10"></a>

###### Baseline visual acuity and injection intensity: real-world United States eyes

> “Greater mean 1-year change in VA also trended with worse baseline VA; those patients with better VA at presentation tended to be particularly vulnerable to vision loss.”
> “Specifically, patients with baseline VA of 20/200 or worse, 20/70 to 20/200, 20/40 to 20/70, and 20/40 or better received 6.5, 7.4, 7.5, and 7.3 anti-VEGF injections, respectively, over 1 year.”
> “Specifically, those patients with baseline VA of 20/40 or better tended to lose VA at 1 year, regardless of anti-VEGF injection frequency. However, these patients also showed better final VA compared with those patients with worse baseline VA.”
> “Mean 1-year change in VA tended to increase in patients with both increased anti-VEGF injection frequency and decreased baseline VA.”

Source: [Ciulla et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31324588/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Anti-VEGF dosing regimens: fixed, as-needed, treat-and-extend, and personalized intervals

> “There are numerous protocols: monthly or bimonthly injections, treat-and-extend, PRN, or personalized treatment interval.”
> “There is no consensus about the ideal treatment intervals with anti-VEGF agents, and the physician can tailor treatment on an individual patient basis.”
> “A continuous, variable dosing regimen that attempts to individualize therapy, commonly referred to as treat-and-extend, is frequently used in clinical practice as an alternative to the two treatment approaches above.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.4-2"></a>

###### NICE: agent selection by cost and switching

> “Given the guideline committee's view that there is equivalent clinical effectiveness and safety of different anti-VEGF agents (aflibercept, bevacizumab and ranibizumab), comparable regimens will be more cost effective if the agent has lower net acquisition, administration and monitoring costs.”
> “Consider switching anti-VEGF treatment for people with late AMD (wet active) if there are practical reasons for doing so (for example, if a different medicine can be given in a regimen the person prefers), but be aware that clinical benefits are likely to be limited.”

Source: [NICE (2018)](https://www.nice.org.uk/guidance/ng82/chapter/Recommendations)

<a id="topic-2.2.2.4-3"></a>

###### Payer coverage restrictions and step therapy prevalence

> “Descriptive assessment showed that approximately 65% of commercial coverage decisions and approximately 52% of MA decisions included restrictions beyond the FDA label.”
> “Coverage decisions for originator products were more likely to include restrictions compared with those for biosimilar products.”
> “Step therapy protocols were found in up to 75% of plans but were variable by drug, with most requiring a first-line trial of bevacizumab.”

Source: [Chambers et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039497/)

<a id="topic-2.2.2.4-4"></a>

###### Medicare Advantage step therapy and prescribing of bevacizumab

> “The difference-in-differences regressions found a 7.8% (95% CI, 4.9%-10.7%; P < .001) greater probability of being prescribed bevacizumab for the first administration due to step therapy.”
> “Step therapy was not significantly associated with an increased rate of medication switching (hazard ratio, 0.86; 95% CI, 0.71-1.06; P = .15).”

Source: [Liu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11316235/)

<a id="topic-2.2.2.4-5"></a>

###### Medicare Part B anti-VEGF use after step therapy

> “After step therapy implementation, relative usage of aflibercept increased by 32.0%, while there was a decrease in relative usage of bevacizumab by 33.2% and ranibizumab by 4.3%.”
> “Step therapy has not significantly increased bevacizumab usage on an aggregate level.”

Source: [Bryan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12592112/)

<a id="topic-2.2.2.4-6"></a>

###### Bevacizumab-first step therapy outcomes at an academic center

> “After 1 year, mean ΔVA was +8.4 letters (95% CI: +6.1 to +10.6 letters). 86% had treatment success, and 6% of eyes had switched to aflibercept.”
> “11% (n = 38) of eyes were switched to aflibercept.”

Source: [Siktberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10275928/)

<a id="topic-2.2.2.4-7"></a>

###### Prior authorization for anti-VEGF agents in retina practices

> “Overall, 2140 (96.2%) requests were approved.”
> “Overall, PA denial for step therapy was 2.9% (65 of 2225) of requests and uncovered diagnoses was 0.9% (20 of 2225) of requests.”

Source: [Dang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11211988/)

<a id="topic-2.2.2.4-8"></a>

###### Step therapy policy review

> “Following the 2019 Centers for Medicare and Medicaid Services decision permitting Medicare Advantage plans to impose step therapy for Part B drugs, many insurers adopted a bevacizumab (Avastin, Genentech/Roche)-first approach to intravitreal anti-VEGF therapy.”
> “However, CMS maintained that FDA-approved biosimilars could be used in step therapy programs.”

Source: [McGuire et al. (2026)](https://retinatoday.com/articles/2026-may-june/anti-vegf-step-therapy-an-update)

<a id="topic-2.2.2.4-9"></a>

###### Patient monitoring during intravitreal therapy

> “Treated patients should be instructed to report symptoms of endophthalmitis, retinal detachment, or decreased vision, and they should be re-examined promptly.”

Source: [American Academy of Ophthalmology (2024)](https://www.aao.org/Assets/404122ae-c018-4175-b526-b1cf866ddc43/639160232059070000/age-related-macular-degeneration-ppp)

<a id="topic-2.2.2.4-10"></a>

###### PULSAR: criteria for shortening the dosing interval and the limit on extension in year 1

> “Beginning at week 16, patients receiving aflibercept 8 mg were assessed and the dosing interval was shortened if the following DRM criteria were met: BCVA loss of more than 5 letters from week 12 and either a more than 25 μm increase in central retinal thickness (CRT) from week 12 or new foveal haemorrhage or neovascularisation”
> “Patients in the aflibercept 8q12 and 8q16 groups who met the DRM criteria at week 16 or week 20 had their interval shortened and subsequently received aflibercept 8 mg every 8 weeks.”
> “The minimum interval for all patients was 8 weeks, and dosing intervals could not be extended within the first year of treatment.”

Source: [Lanzetta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38461841/)

<a id="topic-2.2.2.4-11"></a>

###### TENAYA and LUCERNE: disease activity assessment for interval assignment and the personalised treatment interval regimen

> “After the first four monthly doses (day 1, and weeks 4, 8, and 12), patients in the faricimab group were assessed at weeks 20 and 24 for protocol-defined disease activity based on structural and functional criteria and treating physician clinical assessment”
> “Patients in the faricimab group who did not have active disease at weeks 20 and 24 received faricimab at week 28 and continued a 16-week regimen up to week 60.”
> “In the PTI regimen, dosing intervals can be extended in 4-week increments or reduced in 4-week or 8-week increments to a minimum of every 8 weeks, a maximum of every 16 weeks, or maintained based on disease activity assessments at study drug dosing visits.”

Source: [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/)

<a id="topic-2.2.2.4-12"></a>

###### Archway: monthly monitoring during 24-week refill intervals

> “Patients treated with the PDS Q24W were monitored monthly through trial completion to maintain visual acuity examiner masking, and additional safety visits were performed at days 2 and 7 after implantation.”
> “Archway required monthly monitoring for PDS-treated patients to align with the visit schedule of the monthly ranibizumab comparator arm.”
> “the Archway trial was not designed to evaluate the number of visits required for monitoring PDS-treated patients”

Source: [Holekamp et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34597713/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary

In the phase 3 LUGANO trial (432 participants; vorolanib insert 2.7 mg every 6 months versus aflibercept 2 mg every 8 weeks), the vorolanib insert did not achieve noninferiority for mean change in best-corrected visual acuity at weeks 52 and 56 in the full dataset. An ad hoc analysis excluding 9 of 211 insert-arm participants met the noninferiority criterion (nominal p = 0.0096). Relative to on-label aflibercept, the insert reduced treatment burden by 42% (nominal p < 0.0001), about 2 fewer injections through week 56. Of insert-treated participants, 76% were supplement-free through week 32, 54% through week 56, and 79% received zero or one supplemental injection through week 56. The mean difference in central subfield thickness versus aflibercept was 4 microns at week 56. Rates of cataract, elevated intraocular pressure, and intraocular inflammation did not differ between arms. In the phase 2 DAVIO 2 trial of previously treated participants, the 2 mg and 3 mg doses differed from aflibercept by -0.3 and -0.4 letters, respectively, at weeks 28 and 32, and 65% and 64% of eyes were supplement-free through 6 months. In the identical phase 3 LUCIA trial (475 participants), the vorolanib insert also did not achieve noninferiority: least squares mean BCVA change was +2.5 letters with the insert and +6.1 letters with aflibercept (difference -3.7 letters). Treatment burden was reduced by 38% (nominal p < 0.0001); 52% of insert-treated participants were supplement-free and 71% received zero or one supplemental injection through week 56; and mean central subfield thickness change was -66 µm with the insert and -82 µm with aflibercept (difference +16 µm). All data are topline or preliminary sponsor reports.

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm); [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm); [EyePoint LUCIA topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm); [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm)

<a id="topic-2.2.2.7-2"></a>

###### LUGANO: topline efficacy outcomes through Week 56

| Outcome | Quoted result |
| --- | --- |
| Primary endpoint, full dataset | “the primary endpoint of change from baseline in best corrected visual acuity (BCVA) versus 2 mg aflibercept on-label control was not achieved in the full dataset” |
| Treatment burden | “42% reduction in treatment burden, achieving superiority versus on-label aflibercept (nominal p-value<0.0001) compared to a maximum possible reduction of 60%” |
| Injections avoided | “two fewer injections on average in DURAVYU patients versus on-label aflibercept up to Week 56” |
| Supplement-free through Week 32 | “76% of DURAVYU patients were supplement-free up to Week 32” |
| Supplement-free through Week 56 | “54% of DURAVYU patients were supplement-free up to Week 56” |
| Zero or one supplement through Week 56 | “79% of DURAVYU patients received zero or one supplement up to Week 56” |
| Central subfield thickness | “a mean difference of 4 microns versus on-label aflibercept control in central subfield thickness (CST) at Week 56” |

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-2.2.2.7-3"></a>

###### LUGANO: ocular safety compared with aflibercept

> “No difference in cataracts, elevated intraocular pressure, or intraocular inflammation between study and control group”
> “No observed occurrences of insert migration, anterior chamber opacities, free-floating drug particles, retinal vasculitis, or severe intraocular inflammation (IOI)”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-2.2.2.7-4"></a>

###### LUGANO: visual acuity excluding participants with vision loss unrelated to wet AMD

> “Excluding the cohort, DURAVYU arm gained +3.5 letters”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-2.2.2.7-5"></a>

###### DAVIO 2: Week 32 outcomes in previously treated participants

> “The 2mg and 3mg doses were only -0.3 and -0.4 letters different, respectively, versus on-label aflibercept.”
> “65% and 64% of eyes were supplement free up to six-months, respectively, for the 2mg and 3mg doses of DURAVYU.”
> “Both DURAVYU doses demonstrated strong anatomic control with OCT difference below 10 microns at week 32 compared to the aflibercept control.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.2.2.7-6"></a>

###### DAVIO 2: 12-month supplement-free rate after a single injection

> “After a single injection of DURAVYU, approximately half of the treated study eyes were anti-VEGF supplement free, while 22% of the eyes in the aflibercept control arm were administered a supplement despite these control eyes receiving mandated bi-monthly injections through 12 months.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-2.2.2.7-7"></a>

###### Visual acuity outcomes with extended-interval faricimab and every-8-week aflibercept at week 48

> “In the primary analysis (ITT population), adjusted mean gains in BCVA at primary endpoint visits in TENAYA were 5·8 letters (95% CI 4·6 to 7·1) in the faricimab group and 5·1 letters (3·9 to 6·4) in the aflibercept group (treatment difference 0·7 letters [95% CI −1·1 to 2·5]).”
> “In LUCERNE, vision gains were 6·6 letters (95% CI 5·3 to 7·8) in the faricimab group and 6·6 letters (5·3 to 7·8) in the aflibercept group (treatment difference 0·0 letters [95% CI –1·7 to 1·8]).”
> “In CMH-weighted estimates, 20·0–20·2% of faricimab-treated patients gained 15 or more letters compared with 15·7–22·2% of patients in the aflibercept group”

Source: [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/)

## Related pages
- [Duravyu (vorolanib intravitreal insert): Wet age-related macular degeneration](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Duravyu (vorolanib intravitreal insert): Wet age-related macular degeneration](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/executive-summary.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/clinical-evidence.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/economics.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: References](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/references.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: prevalence by geography](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/prevalence) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/prevalence.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/cost-effectiveness-analyses.md)
